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ABSTRACT  
Jennifer Lee Jones:  Antihypertensives Adherence Trajectories and the Association Between Antihypertensive 
Medications and Fractures Among Older Adults Initiating Therapy 
(Under the direction of Til Stürmer) 
Antihypertensive medications reduce the risk of cardiovascular diseases among hypertensive 
patients. Yet, few older adults are adherent to their antihypertensive therapy.  Failure to remain adherent 
can lead to increased risk of cardiovascular disease, hospitalizations, and mortality. Prior studies have 
relied on adherence measures that fail to distinguish between medication adherence and persistence.   
Furthermore, research suggests that antihypertensives are associated with fractures among older 
adults. However, prior research has found inconsistent results regarding the strength and direction of the 
association between antihypertensives and fractures.  Few studies have examined the initial increased risk 
of fractures associated with starting antihypertensive therapy, and how the association between 
antihypertensive and fractures may change over time. 
We used a 20% random sample of 2007-2013 Medicare Fee-For-Service data to identify 
beneficiaries initiating antihypertensive therapy between 2008 and 2011. Our primary objectives were: 1) 
examine whether group based trajectory models (GBTMs) could be used to identify antihypertensive 
adherence trajectories among older adults initiating therapy, and 2) examine the association between 
antihypertensive initiation and fractures according to antihypertensive class, duration of use, and fracture 
type.  
In our first aim we found that antihypertensive adherence trajectories vary among Medicare 
beneficiaries and that GBTMs are an effective tool for capturing antihypertensive adherence. We 
identified six adherence trajectories ranging from beneficiaries who were fully adherent to beneficiaries 
who never returned after their first prescription.  Compared to traditional adherence measures, GBTMs 
were better at identifying beneficiaries with fluctuating patterns of use. The strongest predictors of non-
iv 
adherence included initiation with a single antihypertensive class, non-White race, and no prior history of 
cardiovascular disease.  
In our second aim we found that the association between antihypertensives and fractures varied 
according to antihypertensive class, time since initiation, and outcome definition (e.g., falls vs. fractures). 
Overall, beneficiaries who initiated with angiotensin-receptor blockers had the lowest rate of fractures in 
the year following initiation. Thiazides were associated with an initial increased rate of falls and fractures, 
but this association decreased over time. Results suggest clinicians may want to consider different 
fracture risks when choosing between antihypertensive drug classes, particularly for older adults with a 
history of falls or fractures. 
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CHAPTER 1: INTRODUCTION  
Hypertension is one of the most commonly diagnosed chronic health conditions in the United 
States.1  Older adults are susceptible to developing hypertension due to changing metabolic and vascular 
functioning associated with age.2  Antihypertensive medication can reduce the risk of cardiovascular 
disease3 and mortality among older adults.2  However, few older adults remain adherent to their 
antihypertensive therapy.  It is estimated that only half of older adults remain adherent to their 
antihypertensive medications after one year of use.4  
Older adults are at higher risk of being non-adherent due to an increased number of comorbidities 
and increased medication use.2   Prior studies have relied on overall measures of adherence such as 
proportion of days covered (PDC) and the medication possession ratio (MPR), which quantify the number 
of days covered with medications over a defined period of time.5,6   However, these measures cannot 
differentiate between adherence and persistence (i.e., changing patterns of medication use over time).6,7  
Recently, group based trajectory models (GBTM) have been used in place of traditional adherence 
measures to better capture natural changing patterns of medication use.7-9 No prior study has used 
GBTMs to examine antihypertensive adherence among older adults initiating therapy.  
Medication-related adverse events, such as fractures or falls, could impact antihypertensive 
adherence among older adults. Recent research suggests that antihypertensive medications are associated 
with falls and fractures.10,11  However, the exact mechanism between antihypertensives and fractures is 
not known, and inconsistent results have been found in regards to specific classes of antihypertensives 
and fracture risk.11,12  Prior research studies were subject to residual confounding, were limited to hip 
fractures, and few accounted for duration of antihypertensive use.  
In this study, we examined whether GBTMs could be used to identify antihypertensive adherence 
trajectories in the first year following initiation, and if certain patient characteristics are associated with 
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better adherence. Additionally, we examined the association between antihypertensives and fractures 
according to antihypertensive class, time since initiation, and fracture type. In sub-analyses, we examined 
whether the association between antihypertensives and fractures varied according to antihypertensive 
adherence and if the outcome definition (falls vs. fractures) varied the results.  
3 
CHAPTER 2: REVIEW OF THE LITERATURE 
2.1 Hypertension in the U.S. 
 Hypertension is one of the most commonly diagnosed chronic health conditions in the United 
States.13 An estimated 65% of older adults are taking antihypertensive medications or have elevated blood 
pressure according to the 2011-2014 National Health and Nutrition Examination Survey.1  Hypertension 
is typically defined as having systolic blood pressure equal to or above 140 mm Hg and diastolic blood 
pressure equal to or above 90 mm Hg.14  However, new recommendations suggest modifying the systolic 
blood pressure criteria for adults over the age of 60 to 150 mm Hg.13  Hypertension is associated with a 
negative health outcomes (such as myocardial infarction, stroke, and kidney disease), and can lead to 
death if left untreated.2,14  
2.2 Risk Factors for Hypertension 
 Previous research has identified certain factors can increase one’s risk of developing 
hypertension. Health-related risk factors include elevated body mass index, hypercholesterolemia, chronic 
kidney disease, and diabetes.2,15  
Prevalence of hypertension tends to 
vary according to race and gender. 
Non-White populations had a higher 
prevalence of hypertension than White 
populations (41% vs. 28%, 
respectively)1, and females over the 
age of 65 have higher rates compared 
to males.14,16,17  See Figure 1 for the 
distribution of hypertension in the U.S. 
 
 
Figure 1: Prevalence of HT according to age and sex in the U.S              
(2007-2012)14  
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by age and gender according to the National Health and Nutrition Examination Survey (2007-2010).14 
Genetics, diet, and lifestyle factors such as alcohol consumption and smoking can also impact one’s risk 
of developing hypertension.2,14  
Advancing age is one of the strongest risk factors for developing hypertension.2  The prevalence 
of hypertension among U.S. adults over 80 years of age was estimated to be 76% in 2010.18  Older adults 
are at greater risk for developing hypertension due to changes in metabolic and vascular functioning 
associated with advancing age.2,19  Additionally, increased presence of comorbidities, the potential for 
medication-related adverse events, and changing drug metabolism rates make it difficult to manage 
hypertension in older adults.2,19,20  Finally, recommendations for hypertension treatment among older 
adults are often based on clinical trials of younger, healthier populations making hypertension 
management in older adults more challenging.2,18,21  
2.3 Hypertension Management 
Several treatment options are available for the management of hypertension. The primary goal of 
hypertension treatment is to reduce the risk of negative cardiovascular outcomes associated with high 
blood pressure.22  Mild cases of hypertension can sometimes be managed by lifestyle changes such as 
increased exercise and diet modifications.13,22  Although non-invasive, lifestyle changes alone are not 
effective forms of treatment for many hypertensive patients. In addition to lifestyle changes, many 
patients require medications for hypertension control.  
 Several classes of medications are 
available for the management of hypertension. 
See Table 1 for a listing of antihypertensive 
medication classes recommended as first line 
therapy treatment for older adults.13  Antihypertensive medications act by lowering blood pressure and 
have been found to reduce the risk of adverse cardiovascular events and mortality among older 
adults.13,23,24  Choice of antihypertensive medication class is dependent on a patients’ age, race, and 
whether a patient has diabetes or chronic kidney disease.2,13   See Figure 9 in the appendix for the 2014 
Table 1: Recommended classes of 
antihypertensives medications for older adults 
Diuretics 
Thiazide diuretics 
β-blockers (BBs) 
Calcium Channel Blockers (CCBs) 
Angiotensin-converting enzyme inhibitors (ACEs) 
Angiotensin receptor blockers (ARBs) 
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Hypertension Guideline Management Algorithm developed by the Eighth Joint National Committee (JNC 
8) appointed by the National Heart Lung and Blood Institute (NHLBI).13    
 The first class of antihypertensive medication recommended for hypertension management 
among older adults without diabetes or chronic kidney disease are thiazide diuretics.2,13 Thiazides are low 
cost and have been found to successfully lower the risk of negative cardiovascular events among 
hypertensive patients.25  However, if a patient has other chronic comorbidities, such as chronic kidney 
disease or heart failure, loop diuretics may be recommended in place or in conjunction with thiazides. 25,26   
Older adults prescribed loop diuretics often have a higher number of  comorbidities and are at greater risk 
of mortality compared to older adults prescribed other classes of antihypertensive drugs.27 In terms of 
adverse events, use of any diuretic can cause electrolyte imbalance due to water loss, unwanted weight 
loss28, orthostatic hypotension, and impotence.2,25  Additionally, loop diuretics have been found to be 
associated with negative side effects such as headaches and anemia.2  
β-blockers (BBs) are prescribed as first-line treatment of hypertension in patients with a history 
of cardiovascular disease, however evidence of their effectiveness in older adults in limited.2,29  
Therefore, they are often prescribed in combination with other classes of antihypertensive medications.2  
BBs are often given as first-line treatment to older adults with migraines, tremors, or other cardiovascular 
diseases (e.g., heart failure, arrhythmia, and coronary artery disease).2  BBs have been found to be 
associated with an increased risk of orthostatic hypotension.30 Another class of antihypertensive 
medication prescribed to older adults with a history of cardiovascular disease are calcium channel 
blockers (CCBs). However, CCBs have been found to be associated with negative side effects such as 
swelling, headache, dizziness, nausea, and orthostatic hypotension.2,31 
In patients with chronic kidney disease or diabetes, angiotensin-converting enzyme inhibitors 
(ACEs) or angiotensin-receptor blockers (ARBs) are recommended as the first-line treatment of 
hypertension. ACEs and ARBs regulate blood pressure through modulation of the renin-angiotensin-
aldosterone system (RAAS).2,32,33  ACEs have been found to be associated with side effects including: 
hypotension, cough, and rash.2  Additionally, ACEs have been found to be associated with balance 
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impairment among older adults.28 ARBs are the newest class of antihypertensives recommended for first-
line treatment.33  Compared to other classes of antihypertensive medications, ARBs appear to be 
associated with fewer unwanted side effects and have higher levels of adherence.6,33,34  
Several other forms of antihypertensive medications exist, however these medications are not 
commonly recommended as first-line treatment or are prescribed in combination with other classes of 
antihypertensive medications. Hypertensive older adults are normally prescribed one class of medication 
initially, but older adults may be prescribed a combination of antihypertensive medications if blood 
pressure is not controlled with the one class alone or among severe cases of hypertension.13  
2.4 Antihypertensive Medication Adherence 
 In order for antihypertensive medications to be effective, it requires that patients follow their 
medication schedule as prescribed by their health care professional. However, prior research has found 
that many hypertensive patients do not take their medications as prescribed.35  In a recent meta-analysis of 
antihypertensive adherence, Lemstra and Alsabbagh found that antihypertensive adherence ranges from 
48%-49% after one year of follow-up.4  Medication adherence is typically defined as taking one’s 
medication as prescribed by a healthcare provider.  Failure to remain adherent can lead to increased risk 
of hospitalizations, loss of independence, and higher medical costs.35,36 Antihypertensive adherence tends 
to vary according to duration of use and has been found to be vary by patient demographics, type of 
medication class, and personal health characteristics.5,34  
Factors that place individuals at higher risk of being non-adherent include increased age, presence 
of comorbidities, mental health disorders, cognitive impairment, treatment regimen (e.g., number of pills, 
strength, and schedule), medication cost, and adverse side effects.2,5,34,36,37  Hypertension is asymptomatic 
making it difficult to assure adherence to treatment. Patients stopping therapy early may not feel any 
direct effects.  Therefore, one of the main reasons for poor adherence to antihypertensive therapy are 
adverse side effects from the medications.34,35,37   
 Given the importance of antihypertensive adherence for clinical benefits, previous studies have 
been conducted to identify measures to quantify medication adherence. Both direct and indirect measures 
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of medication adherence exist. Direct measures involve clinical laboratory tests and are often costly and 
time-consuming for researchers.5,34  Indirect measures of medication adherence are evaluated using 
pharmaceutical claims data or self-reported medication data.5,34  Compared to direct measures, indirect 
measures are lower in time and cost.5 Currently, no established standard exists for defining adequate 
medication adherence. However, 80% adherence is often used as the cut-point for classifying patients as 
adherent versus non-adherent.5,38  Previous research has found the 80% threshold to have a high 
sensitivity and specificity for defining adherence to antihypertensive medications.39 Additionally, the 80% 
threshold is associated with improved cardiovascular outcomes among hypertensive patients.40  
Patterns of medication use change with time, therefore it is important that methods for 
quantifying medication adherence take into account changing patterns of use according to time.34 
Traditional measures of medication adherence, such as proportion days covered (PDC) and medication 
possession ratio (MPR), fail to account for changing patterns of use with time (Table 2).41,42   Therefore, 
to better capture the natural changing patterns of medication use over time, Franklin et al. used group 
based trajectory models (GBTM) to assess statin adherence with claims data.7,41  Franklin et al. used 
prescription claims to quantify medication adherence to statins.  The authors found that statin users fell 
into six adherence trajectory groups ranging from individuals that were always adherent to individuals 
that had no refills during the study period. When compared to traditional measures of adherence, GBTMs 
were the best at distinguishing between adherent and non-adherent statin initiators.7   
More recently, Franklin et al. used GBTMs to predict cardiovascular events among statin users 
and found similar results. 41  GBTMs were better than traditional adherence measures at predicting 
negative cardiovascular events following initiation.41  However, these studies were limited to younger 
statin users and it is unknown if these same adherence trajectories would hold true for older adults 
initiating with other chronic medications. As mentioned above, older age is a strong predictor of poor 
adherence due to increased presence of comorbidities and polypharmacy. Therefore, it is important to 
adequately capture patterns of medication use among this age group to identify individuals that are at 
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greater risk of stopping therapy early in treatment.  This is the first study to used GBTMs to identify 
antihypertensive adherence trajectories among older adults initiating therapy.  
Table 2: Common measures of medication adherence using claims data 
Term Definition Limitations41 
Proportion of days 
covered (PDC) 
# 𝑑𝑎𝑦𝑠 𝑚𝑒𝑑𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑖𝑠 𝑎𝑣𝑎𝑖𝑙𝑎𝑏𝑙𝑒 𝑡𝑜 𝑝𝑡
𝑇𝑜𝑡𝑎𝑙 # 𝑑𝑎𝑦𝑠 𝑖𝑛 𝑠𝑡𝑢𝑑𝑦
 
Fail to account to varying 
adherence patterns over time. 
Persons with different adherence 
patterns can be given the same 
adherence value. 
 
MPR can overestimate 
adherence. Does not take into 
account overlaps in prescriptions 
Medication 
Possession Ratio 
(MPR) 
𝑇𝑜𝑡𝑎𝑙 # 𝑑𝑎𝑦𝑠 𝑠𝑢𝑝𝑝𝑙𝑦 
𝑇𝑜𝑡𝑎𝑙 # 𝑑𝑎𝑦𝑠 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑓𝑖𝑟𝑠𝑡 𝑎𝑛𝑑 𝑙𝑎𝑠𝑡 𝑝𝑟𝑒𝑠𝑐𝑟𝑖𝑝𝑡𝑖𝑜𝑛
 
 
2.5 Fractures Among Older Adults 
 Fractures are a major public health concern for older adults due to an increased risk of 
complications resulting from a fracture. Fractures are associated with an increased risk of mortality and 
loss of independence.43,44  For instance, one meta-analysis conducted by Haentjens et al. found that hip 
fractures among older adults were associated with a 3% increased risk of death in women and a 7% 
increased risk of death in men in the one year  following the injury.45  Hip fractures are especially 
dangerous for older adults and are the primary reason older adults are hospitalized following a 
fracture.46,47  Despite a decrease in hip fractures in the last decade, it is estimated that  289,000 older 
adults will have a hip fracture by 2030.48  Furthermore, any fracture among older adults is associated with 
high medical care costs. One study found that fractures made up 80% of all hospitalization costs among 
older adults with fall-related injuries.49  
Fractures among older adults are often the result of a fall.  It is estimated that one out of every 
three older adults fall each year, and that 38% of the falls result in some form of injury.50 Older adults are 
at greater risk of sustaining a fall-related injury due to an increased risk of osteoporosis.51,52  Osteoporosis 
is a chronic health condition characterized by low bone mineral density (BMD) and greatly increases the 
risk of fractures resulting from falls.53  Risk of osteoporosis increases in parallel with age and is common 
among post-menopausal women.54 Osteoporotic fractures typically occur at the hip, vertebrae, or 
wrist.53,54    In addition to osteoporosis, previous research has found that certain characteristics place older 
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adults at greater risk of a fracture. One of the strongest predictors of fractures is having a previous 
fracture. Once an older adult sustains a fracture, the risk for a subsequent fracture nearly doubles.55  
Additional risk factors for fractures include: advanced age, female gender, and White race.52,56  
2.6 Antihypertensive Medications and Fractures 
Use of psychotropic medications and taking multiple medications can increase the risk of both 
falls and fractures among older adults.57-59  Recent evidence suggests that antihypertensive medications 
may increase the risk of falls and fractures among older adults.60,61  Tinetti et al. found that among 
community-dwelling hypertensive older adults, use of antihypertensive medications was associated with 
an 11% increased risk of serious fall-related injuries. The authors found that the association between 
antihypertensives and injury was not significant when stratified according to antihypertensive class.60  
However, this study was limited to prevalent users of antihypertensives and was unable to capture falls 
that occurred early in treatment.  In another study, Marcum et al. found that any use of antihypertensives 
were not associated with recurrent falls among non-frail older adults 70 years of age and older (odds ratio 
(OR): 1.13, 95% confidence interval (CI): 0.88-1.46). However, when stratified by antihypertensive class, 
loop diuretic users had higher odds of two or more falls.62  
Previous research has found inconsistent results regarding the strength and direction of the 
association between antihypertensives and subsequent falls and fractures among older adults (Appendix 
Table 16). Some studies have found antihypertensives increase the risk of falls or fractures60,61,63, while 
others have found no association62,64-66, or a protective association for fractures or falls.67   Choi et al. 
examined the risk of fractures associated with antihypertensive initiation among newly diagnosed 
hypertensive adults over the age of 50.61 The authors’ found that the risk of fractures varied according to 
antihypertensive class. Specifically, ARBs, BBs, and CCBs were not associated with an increased rate of 
fractures.61  However, this study failed to examine fractures in the first six months following initiation, 
and only included antihypertensive users that were at least 80% adherent.  In another study of 
hypertensive adults over 70 years of age, Lipsitz et al. found that the odds of self-reported injury falls 
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were lower among older adults taking ACEs or CCBs. However, the study was limited to 598 older adults 
and was reliant on self-reported falls and medication history.64 
In 2008, Wiens et al. conducted a meta-analysis of previous studies examining the association 
between antihypertensives and fractures.  The authors found that overall, thiazide diuretics and BBs 
reduced the risk of fractures by 14% using pooled risk ratios across studies.10  However, the authors were 
not able to examine the risk of fractures associated with the other classes of antihypertensive given the 
low number of studies available to examine these effects.  
In 2015, Butt and Harvey conducted an updated literature review of previous studies examining 
the association between antihypertensives and adverse events, including falls and fractures. 11  The 
authors found that in general, thiazides are associated with an initial increased risk of falls and fractures in 
the first few weeks after starting antihypertensive therapy.11  However, few studies have examined the 
fracture or fall risk in the immediate period after initiation of therapy. Additionally, previous studies have 
been limited to hip fractures only. The authors found that chronic use of antihypertensives appears to be 
associated with an overall decreased risk of falls and fractures, however results have been inconsistent in 
regards to drug class.11  No prior study has examined the effect outcome definition (falls vs. fractures) has 
on the association between antihypertensives and subsequent adverse events.  
Antihypertensive medications are believed to impact fracture risk through two possible 
mechanisms. First, initial use or changing doses of antihypertensives can result in orthostatic hypotension 
which can increase the risk of falls and subsequent fractures.12  Orthostatic hypotension is caused by a 
drop in blood pressure upon standing and is associated with an increased risk of falls among older 
adults.68  Second, chronic use of antihypertensives can impact fracture risk through biologic interactions 
with BMD.12  Much of the prior literature on fractures and antihypertensives have been limited to 
diuretics or BBs, and it is still not clear which mechanism or antihypertensive drug class poses the 
greatest risk of injury for older adults.10  
 One of the possible mechanisms antihypertensives can increase the risk of fractures is by 
interactions with BMD.  Prior research has found that antihypertensives may have direct effects on 
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BMD.32   For instance, thiazide diuretics decrease urinary calcium excretion and have been found to 
stimulate the formation of osteoblasts, or bone cells. BBs are thought to impact BMD by preventing bone 
loss through regulation of the sympathetic nervous system.  Additionally, studies have found that ARBs 
and ACEs can impact BMD and subsequent fracture risk by inhibiting bone turnover caused by the renin-
angiotensin-aldosterone system (RAAS).32  However, the time it takes for antihypertensives to have BMD 
effects is not known.  No prior study has examined the impact pattern of antihypertensive adherence has 
on fracture risk. This is the first study to examine the association between antihypertensive adherence and 
fractures among older adults. See Table 3 for a summary of antihypertensive medication classes and their 
potential associated impact on BMD.32  
Table 3: Antihypertensive medications and their impact on bone health and fractures 
Class Impact on bone health 
Effect on 
BMD 
Effect  on 
fracture 
risk Comments 
Thiazide 
Diuretics 
Reduce calcium urinary loss 
and stimulate osteoblasts and 
bone formation 
Strengthen Decrease 
Highly researched in 
observational and 
experimental settings. 
BBs 
Decrease bone loss by 
regulating the sympathetic 
nervous system 
Strengthen Decrease 
Based on animal and 
observational studies. No 
randomized controlled 
trials. 
ACEs/ 
ARBSs 
Inhibit bone resorption by 
angiotensin-I 
Strengthen Decrease 
Researched in animal 
studies. Mixed results 
found in observational 
studies. 
CCBs 
Inhibit bone resorption, 
increase calcium 
concentration in bone 
Possibly 
strengthen 
Unknown 
Limited experimental and 
observational studies. 
Mixed results found in 
clinical studies.  
Table is based off the manuscript published by Ghosh32 
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CHAPTER 3: SPECIFIC AIMS 
 In our first aim we used GBTMs to model patterns of antihypertensive adherence among older 
adults initiating antihypertensive therapy. Our second dissertation aim examined the association between 
starting antihypertensive therapy and incident fractures among older adults.  Results can be used to 
identify older adults at greater risk of being non-adherent to their antihypertensive therapy and whether 
certain subclasses of antihypertensives are associated with higher risk of fractures after initiation. This 
research was conducted through the two aims listed below.  
3.1 Aim 1: Examine Patterns of Antihypertensive Adherence Among New-Users of Antihypertensive 
Medications.  
Aim 1.1 Identify patterns of antihypertensive adherence among new users of antihypertensive 
medications using GBTMs 
Aim 1.2 Determine factors associated with patterns of antihypertensive use by comparing the 
distribution of covariates across adherence trajectory groups 
Aim 1.3 Compare GBTMs to traditional methods of quantifying medication adherence (eg., 
proportion months covered and proportion of days covered), using the actual number of 
prescribed days as the gold standard 
Hypotheses: 
1) Patterns of antihypertensive adherence vary among older adults.  
2) Older adults with poor antihypertensive adherence will be older, take multiple medications, and be 
in overall poorer health compared to adherent older adults. 
3) GBTMs will be better at capturing patterns of antihypertensive adherence compared to traditional 
measures of quantifying medication adherence using claims data 
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Rationale: Antihypertensive medication reduce the risk of cardiovascular disease3 and mortality among 
older adults.2  However, few older adults remain adherent to their antihypertensive therapy.  It is 
estimated that only half of older adults remain adherent to their antihypertensive medications after one 
year of use.4  Older adults are at higher risk of being non-adherent due to an increased number of 
comorbidities and increased medication use.2   Prior studies examining predictors of antihypertensive 
adherence have relied on overall measures of adherence such as proportion of days covered (PDC) and 
medication possession ratio (MPR), which quantify the number of days covered with medications over a 
defined period of time.5,6   However, these measures cannot differentiate between adherence and 
persistence (i.e., changing patterns of medication use over time).6,7  The benefit of using GBTMs over 
traditional methods is that we will be able to capture the time-varying nature associated with medication 
use.  No prior study has used GBTMs to identify antihypertensive adherence among older adults initiating 
antihypertensive therapy. Results can be used by clinicians or public health researchers to begin to 
identify sub-populations of older adults at risk of being non-adherent to antihypertensive therapy.   
Data: 20% random nationwide sample of Fee-For-Service Medicare data including parts A, B, and D.  
Journal: Results from this aim are under review at The American Journal of Hypertension. 
3.2 Aim 2: Examine the Association Between Antihypertensive Use and Fractures Among New Users of 
Antihypertensives.  
Aim 2.1: Estimate the rate of fractures according to antihypertensive adherence trajectories 
identified in Aim 1 
Aim 2.2: Estimate the rate of fractures according to antihypertensive class and time since 
initiation   
Aim 2.3: Examine the association between antihypertensives and type of fracture outcome 
(probable low BMD vs. normal BMD) according to antihypertensive class 
Aim 2.4: Examine the impact of using falls versus fractures as the primary outcome on the results 
of aim 2.2 
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Hypotheses: 
1) The rate of fractures will be lowest among new users of ARBs compared to other classes of 
antihypertensive medications.  
2) The rate of fractures will vary by antihypertensive class depending on the time since initiation. For 
instance, thiazide diuretics will initially be associated with an increased risk of fractures due to 
orthostatic hypotension. However, at the end of one year of use, thiazide diuretics will have a 
lower rate of fractures due to potentially protective effects from interactions with BMD.  
3) Types of fracture will vary depending on the antihypertensive class.  For instance, thiazide users 
will have a lower rate of probable low BMD fractures due to potentially protective effects of 
thiazides on BMD.  
4) Outcome definition (falls vs. fracture) will impact the associations between antihypertensive class 
and adverse events. Given that only one third of falls result in a fracture, the results when using 
falls as the outcome may not be the same as the results when using fractures as the primary 
outcome.   
Rationale: Fractures and falls are a major public health concern for older adults. Recent evidence suggests 
that antihypertensive medications may increase the risk of serious falls and fractures among older 
adults.60,61  However, previous studies have found inconsistent results regarding the strength and direction 
of the association. Some studies have found antihypertensives increase the risk of falls or fractures60,61,63, 
while others have found no association62,64-66, or a protective association.67   Few studies have examined 
the immediate fracture or fall in the first few weeks after initiation of therapy.  Additionally, the majority 
of previous studies have been limited to hip fractures only or self-reported falls. This is the first study to 
examine the effect outcome definition (falls vs. fractures) has on the association between 
antihypertensives and subsequent adverse events. Additionally, no prior study has examined the 
association between antihypertensive adherence trajectories and subsequent fractures.  Results from this 
aim can be used to identify if certain classes of antihypertensives are associated with greater risk of 
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adverse events among older adults. If certain antihypertensives increase the risk of adverse events, 
clinicians need to be aware of these risks when prescribing to older adults.  
Data: 20% random nationwide sample of Fee-For-Service Medicare data including parts A, B, and D. 
Journal: Results from Aim 2.2 and 2.3 are to be submitted to the journal of Injury Epidemiology.    
.
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CHAPTER 4: ANTIHYPERTENSIVE ADHERENCE TRAJECTORIES AMONG OLDER 
ADULTS IN THE FIRST YEAR AFTER INITIATION OF THERAPY 
4.1 Introduction 
Hypertension is one of the most common chronic health conditions among older adults. An 
estimated 65% of older adults are taking antihypertensive medications or have elevated blood pressure.1  
The prevalence of hypertension increases with age due to changes in metabolic and vascular 
functioning.2,19  Hypertension increases the risk for cardiovascular diseases (e.g.,  stroke, myocardial 
infraction), kidney disease, and death.69 
Antihypertensive medications reduce the risk of cardiovascular disease among hypertensive 
patients.13,23,24  Yet, few older adults are adherent to their antihypertensive medication.6   A meta-analysis 
found that antihypertensive adherence was approximately 49% after one year of follow-up.4  Failure to 
remain adherent can lead to increased risk of cardiovascular disease, hospitalizations, and 
mortality.23,40,70,71  Older adults are at greater risk of nonadherence due to polypharmacy and increased 
comorbidities.2  Female gender, low income, presence of comorbidities, mental health disorders, non-
White race, and cognitive impairment are associated with non-adherence. 2,4,5,34  
Prior studies have used overall measures of adherence, such as proportion days covered (PDC) 
and medication possession ratio (MPR), which quantify the number of days covered with medications 
over a defined period of time.5,6  However, these measures cannot quantify the time-varying nature of 
medication adherence.6,42 Good control of the time-dependent nature of medication adherence may be 
critically important in studies of factors that strongly depend on age.  
Group based trajectory models (GBTM) quantify time-varying patterns in medication 
adherence.8,9,41   In a study of adults initiating statins, GBTMs were better at distinguishing between 
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adherent and non-adherent users than time-static adherence measures.42  GBTMs account for dynamic 
patterns of medication use and thus do not make assumptions about the trajectory shape.42,72   
Despite these advantages, no prior study has used GBTMs to model antihypertensive adherence 
trajectories among older adults initiating therapy. Our objectives were to 1) use GBTMs to identify 
antihypertensive adherence trajectories in the first year following initiation, 2) compare adherence 
trajectories to traditional adherence measures, and 3) examine whether patient characteristics predict 
adherence trajectories.  
4.2 Methods 
Data  
We used a 20% nationwide, random sample of fee-for-service Medicare beneficiaries who were 
enrolled at least one month in Medicare parts A (inpatient care), B (outpatient care), and D (prescription 
drug) coverage between 2007 and 2011. Medicare is the federally provided health insurance available to 
all U.S. residents over the age of 65 and fee-for-service is the part of Medicare where individual insurance 
claims are sent directly to the Centers for Medicare and Medicaid Services (CMS). Data were obtained 
under a data use agreement established between CMS and the University of North Carolina at Chapel Hill 
(UNC). The study protocol was approved by the UNC’s Non-Biomedical Institutional Review Board 
(#15-1704).  
Cohort 
The study cohort consisted of all new users of antihypertensive medications initiating therapy 
during 2008-2011 who were continuously enrolled in Medicare Parts A, B, and D for at least 12 months 
prior to initiation of therapy (index date). New use was defined as not having a prior prescription of the 
following antihypertensive medications in the last 12 months: angiotensin converting enzyme inhibitors 
(ACE), angiotensin receptor blockers (ARB), beta blockers (BB), calcium channel blockers (CCB), or 
thiazide diuretics (THZ) (Appendix Table 18).  
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We limited the cohort to first time new users of antihypertensives (beneficiaries potentially could 
qualify as new users more than once). We required beneficiaries to be at least 66 years of age to ensure 
one full year of Medicare enrollment prior to initiation. Beneficiaries with nursing home stays and those 
with metastatic cancer claims in the last 12 months were excluded since these factors could affect 
medication adherence. Finally, we required beneficiaries to remain enrolled in Medicare for at least one 
year following initiation to capture patterns of antihypertensive use (Figure 2).  
Antihypertensive Adherence 
Patterns of antihypertensive use were defined using date of dispensing and days supply data.  
Starting on the index date, we counted the number of days each month a beneficiary was covered by any 
of the following antihypertensive drug classes: ACEs, ARBs, BBs, CCBs, or THZs. We choose these 
classes based on recommendations for hypertension treatment in older adults.2  Months were defined in 
30-day intervals. If a new prescription was filled prior to the end of the last days’ supply, the day of the 
new prescription began the day after the prior prescription would have ended.  
After counting the number of days covered each month, binary indicator variables were used to 
specify whether an individual was covered by an antihypertensive for at least 24 out of 30 days (e.g., 80% 
days covered). The 80% threshold is considered to have high sensitivity (92%) and specificity (89%) for 
distinguishing between adherent and non-adherent antihypertensive patients73 and is associated with 
improved cardiovascular health.40  We also calculated two common adherence measures: proportion 
months covered (PMC) and proportion days covered (PDC).  PMC was defined as the number of months 
a beneficiary had at least 80% days covered divided by 12 (total months of follow-up). PDC was defined 
as the number of days covered with an antihypertensive medication divided by 360 (total days of follow-
up). 
Predictors of Adherence Trajectories 
We selected predictors of antihypertensive adherence trajectories based on previous literature.2-5,74  
Potential predictors were defined based on claims during the 12 months prior to initiation. Demographics 
(age, gender, and race) were identified using the Medicare Denominator File. We categorized 
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antihypertensive medication initiated on the index date as combination therapy (more than one class of 
antihypertensive) or monotherapy. Concurrent medication use was defined as the number of distinct drugs 
prescribed in the 14 days prior to the index date.  Also, we identified whether beneficiaries were in the 
Medicare coverage gap during the baseline period. Medicare will cover most drug-related expenses until a 
beneficiary reaches a threshold amount in drug-related costs each year, at which time Medicare will no 
longer cover these expenses unless the costs exceed another threshold amount. 75  As a proxy for 
sociodemographic status, we identified whether beneficiaries were eligible for the Medicare low-income 
subsidy (LIS) program. LIS offers medication at a reduced cost for beneficiaries that are eligible due to 
income, family size, and household resources. Finally, we identified whether beneficiaries had 
prescriptions for the following medications: loop diuretics, antiarrhythmics, antidepressants (includes: 
selective serotonin reuptake inhibitors, tricyclics, monoamine oxidase inhibitors, serotonin and 
norepinephrine reuptake inhibitors), antiepileptics, anxiolytics, benzodiazepines, opioids, and hypnotics.  
Using the International Classification of Diseases 9th revision diagnostic codes (ICD-9, Appendix 
Table 19), chronic health predictors included: diabetes, chronic kidney disease, Parkinson’s disease, 
Alzheimer’s disease, chronic obstructive pulmonary disease (COPD), congestive heart failure, 
arrhythmia, osteoarthritis, rheumatoid arthritis, stroke, myocardial infarction, hypertension, obesity, and 
fractures.  
We used the frailty index score (FIS) as a proxy measure of frailty.76  FIS was developed using 
Medicare data to predict limitations in activities of daily living based on factors associated with frailty 
including: demographics, chronic health conditions, geriatric syndromes, medical equipment use, and 
health screenings.  Additionally, we examined the prevalence of variables that were positively 
(ambulance transfer, wheelchair/walker use, home oxygen use, hospital bed, difficulty walking, and 
vertigo) and inversely (cancer screenings) associated with limitations in activities of daily living.76  
Finally, we assessed history of hospitalizations by examining hospital admissions, long-term 
hospital stays, and short-term hospital stays in the year prior to the index date.  
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Analysis 
Trajectory Models 
We used group based trajectory models (GBTMs) to group beneficiaries by patterns of 
antihypertensive use. GBTMs are a type of mixed models originally developed to model changes in 
behavior.72,77  We chose to use GBTMs over other modeling techniques, such as growth mixed modeling, 
because GBTMs do not require prior assumptions about trajectory shapes.72  
GBTMs were estimated using logistic regression models. Dependent variables were the monthly 
binary indicators of antihypertensive use, and the independent variables were months since initiation. 
GBTMs were not adjusted for baseline covariates. Time was modeled using linear and cubic terms. In 
order to identify the best fitting model, we started with a two-group model and subsequently added up to 
seven groups. The maximum of seven groups was imposed to avoid small group sizes.  We used Bayesian 
Information Criterion (BIC), group size, and the average posterior probability to identify the optimal 
number of groups. BIC is a measure of model fit with lower scores signifying better fit. The average 
posterior probability signifies how well beneficiaries fit within the trajectory group they are assigned. The 
typical threshold used to define good model fit is 0.7.72   
We examined spaghetti plots (i.e., stacked individual line plots of the number of days covered 
with antihypertensives each month) for a random sample of 500 beneficiaries to verify that the average 
trends of use aligned with the trajectories identified with the best-fitting GBTM (results not shown). As a 
sensitivity analysis, we repeated the GBTM analyses removing beneficiaries who were in the Medicare 
insurance gap during the follow-up period to verify that the GBTM results were not driven by these 
individuals. Trajectories were defined using “Proc Traj”.78 
Comparison of Adherence Measures 
We compared the GBTM results to traditional adherence measures, PDC and PMC, using the 
monthly binary indicators as the gold standard. We separated months into adherent versus non-adherent 
months and assigned adherence measures to each month (e.g., PDC, PMC, and trajectory measures). 
GBTM values varied across months, but PDC and PMC did not since these measures are static. Area 
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under the receiving operating characteristic curves (AUC) compared adherence measures ability to 
discriminate between adherent versus non-adherent months, with a value of one corresponding to perfect 
discrimination.79-81  
Predictors of Adherence  
We evaluated predictors of adherence by first examining the distribution of covariates across 
trajectory groups.  Next, we used multivariable logistic models to examine associations between baseline 
covariates and trajectory groups. Adjusting for all baseline covariates, we calculated odds ratios (ORs) 
and 95% confidence intervals (95% CIs). The outcome of interest was being in a specific trajectory group 
versus the most adherent group. Strength of the ORs were determined by examining the distance from the 
null value (OR=1) and by examining their precision (width of the 95% CIs).  AUC statistics quantified 
the ability of the predictors to discriminate between trajectory groups.  
Since previous medication persistence is predictive of future use82,83, we examined whether prior 
statin persistence improved prediction of antihypertensive trajectories in a subgroup of beneficiaries who 
had any statin filled at least 180 days prior to the index date. We chose to examine statins since these 
medications are frequently prescribed to older adults. We defined statin persistence as having at least 180 
days continuously covered by a statin, allowing for a 30-day grace period between prescription fills.  
4.3 Results 
We identified 282,520 Medicare beneficiaries initiating antihypertensive therapy during 2008-
2011. On average beneficiaries were 75 years old, 60% were women, and the majority were White (84%).  
Most beneficiaries initiated therapy with one antihypertensive class (86%) and the mean days supplied on 
the index date was 32.   
Antihypertensive Adherence Trajectories 
After fitting GBTMs with different groupings, we identified the six-group trajectory model as the 
best fit (Figure 3, Appendix Table 20). Beneficiaries were grouped as adherent (40%, mean adherence: 
0.97); early drop-off then rebound to almost full adherence (10%, mean adherence: 0.73); partial drop-off 
(10%, mean adherence: 0.35); gradual drop-off (14%, mean adherence: 0.63); rapid drop-off (8%, mean 
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adherence: 0.27); and immediate drop-off (18%, mean adherence: 0.10).  All trajectory groups had an 
average posterior probability greater than 0.8 (Table 4). When we removed beneficiaries in the insurance 
gap period during follow-up (n=43,595, 15%), the six-group model remained the best fitting model and 
the trajectories were similar to those identified using the full cohort (Appendix Figure 9).  
Comparison of GBTMs to Traditional Adherence Measures 
Compared to PDC and PMC, the 6-group trajectory model was better at discriminating between 
adherent and non-adherent months, with an AUC of 95%, compared to 91% for PDC and 92% for PMC 
(Table 4). In results stratified according to trajectory group, the trajectory model outperformed PDC and 
PMC for all groups except the adherent group (Appendix Table 21; AUC-statistics for the adherent group: 
PDC: 87%, PMC: 89%, GBTM: 66%).  
Predictors of Adherence Trajectories 
Individual factors that varied between trajectory groups were race, initiation with combination 
therapy, days supply on the index date, opioid use, history of COPD or cardiovascular disease (e.g., 
arrhythmia, hypertension, or myocardial infarction), vertigo, prior cancer screenings, and hospital 
utilization (Table 5).   
In the adjusted, multivariable analysis, initiation with monotherapy, non-White race, and having 
no prior history of cardiovascular disease were most predictive of being non-adherent (OR>1.0 indicates 
non-adherence). Non-White beneficiaries (aOR: 2.05, 95%CI: 1.99-2.12) and those initiating with one 
class of antihypertensive drug (aOR: 2.08, 95%CI: 2.00-2.13) were approximately twice as likely to be in 
the immediate drop-off group compared to the adherent group. Other factors strongly predictive of non-
adherence were having a high probability of being frail, Parkinson’s disease, opioid use, no prior history 
of being in the Medicare insurance gap, vertigo, COPD, polypharmacy, and no prior history of having 
hospital admissions during baseline (Table 6, Appendix Table 22).  
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Prior Statin Persistence and Adherence Trajectories 
Statins were dispensed at least 180 days prior to the start of antihypertensive use for 25% of 
beneficiaries (n=69,668).  Of those, 68% (n=47,668) were persistent for at least 180 days.  Prior statin 
persistence was predictive of being more adherent (Table 7). After adjustment, prior statin persistence 
was strongly associated with not being in the partial drop-off group versus adherent (aOR: 0.40, 95% CI 
0.37-0.42).  
4.4 Discussion  
Overall, GBTMs are effective for identifying patterns of antihypertensive adherence among 
Medicare beneficiaries initiating therapy. We identified six distinct adherence trajectories ranging from 
fully adherent to those beneficiaries that never returned after their first prescription.  Nearly half of 
beneficiaries remained adherent in the year following initiation. Compared to traditional adherence 
measures, GBTMs were better at distinguishing between fluctuating adherence patterns. Individual 
factors predictive of adherence included initiation with combination therapy, White race, and history of 
cardiovascular disease. 
To our knowledge, no previous study has used GBTMs to identify antihypertensive adherence 
trajectories among older adults. The six trajectories identified are approximately similar to previous 
studies that have used GBTMs to model medication adherence to other drugs.8,42,83,84  Similar to other 
studies 42,84, we found that GBTMs were better than PMC and PDC at distinguishing between adherent 
and non-adherent patients, especially for patients with fluctuating adherence. Factors such as physician 
visits, health screenings, and hospitalizations can influence patients stopping and re-initiating with 
statins85, however, research is needed to examine if the same results hold true for other chronic 
medications. Future research could use GBTMs to identify time-dependent factors influencing 
fluctuations in medication behavior.  
Similar to past studies, we found that beneficiaries with cardiovascular diseases and those who 
initiated therapy with more than one class of antihypertensive were more likely to be adherent.3,74 These 
older adults may be more aware of the importance of being adherent due to more severe hypertension and 
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poor cardiovascular health.   However, a large proportion of beneficiaries with cardiovascular disease 
were not adherent.  For instance, 21% of beneficiaries in the immediate drop-off group had a history of 
arrhythmia and 10% had congestive heart failure.  Our results suggest physicians should encourage older 
adults to remain adherent to antihypertensives, particularly among those with poor cardiovascular health.  
Our results confirm previous studies that noted past medication behavior is predictive of future 
medication adherence.82,83  Bushnell et al. found that prior persistence to chronic medication was 
associated with improved antidepressant persistence among adults.82  Similarly, Franklin et al. found that 
the addition of initial statin adherence improved the prediction of future statin adherence trajectories.83 
We found that prior statin persistence was predictive of antihypertensive adherence. Since statins are 
commonly prescribed to older adults, results suggest that clinicians can consider prior persistence to other 
chronic medications to identify patients who are more or less likely to remain adherent to 
antihypertensives therapy.   
This study has limitations. An antihypertensive prescription dispensed does not guarantee that the 
beneficiary is taking the medication as prescribed. However, since a co-payment is required for most 
dispensed prescriptions, it is reasonable to assume that patients actually take their antihypertensives after 
the first refill. Antihypertensive medications obtained outside of Part D (e.g., medication purchased out-
of-pocket, through private insurance, or samples provided by physicians) were not captured. Fortunately, 
most antihypertensives are generic and sample use is less likely.86,87 
Our results may be subject to residual confounding related to uncontrolled frailty measures and 
time-varying factors affecting medication adherence. Physician visits, frailty, and medication-related 
adverse events, such as orthostatic hypotension and fractures, are time-varying factors that likely affect 
antihypertensive adherence. For instance, we found that history of fractures was weakly associated with 
being non-adherent. This finding could potentially be due to individuals with a history of fractures 
stopping use of antihypertensive medication because of unwanted side effects that increased their risk of 
additional fractures. Older adults who experienced adverse events may have stopped therapy during the 
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initial period of use. Further research is needed to examine the impact time-varying covariates, including 
those affected by prior treatment, have on antihypertensive adherence trajectories.  
Similar to the 2012 U.S. older adult population as a whole88, the majority of our cohort was White 
(84% vs. 86%) and women (60% vs. 57%). It is unknown if these trajectories would hold true for non-
White populations. Research featuring large non-White populations is needed to identify underlying 
factors that contribute to non-adherence among various race/ethnicity sub-populations.  
Lastly, results of our comparison of traditional adherence measures to GBTMs should be 
interpreted with caution. We included PDC and PMC in our analysis to highlight one of the inherent 
disadvantages of using these static adherence measures in that they fall short of separating adherence 
from persistence. Further research is needed using external indicators, such as mortality outcomes or 
cardiovascular events, to validate the use of GBTMs over traditional adherence measures.  
Our finding that nearly half of Medicare beneficiaries were adherent to their antihypertensive 
medication in the year following initiation is encouraging. GBTMs are an effective tool for visualizing 
and capturing patterns of antihypertensive use among older adult populations. Future studies can use 
GBTMs to identify factors influencing patients to return to being adherent after an initial decline and to 
assess if adherence trajectories are associated with improved clinical outcomes. Researchers and 
clinicians may find these results helpful in identifying target populations for interventions designed to 
increase adherence among older adults.    
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Table 4: Antihypertensive adherence trajectories in the 12 months following initiation according to 
adherence measures 
Trajectory Group 
Group Size 
Average 
Probability of 
Adherencea 
Proportion 
Days 
Covered 
(PDC) 
Proportion 
Months 
Covered 
(PMC) 
Average 
Posterior 
Probabilityb 
N % 
Mea
n Std Mean Std Mean Std Mean Std 
Immediate Drop-
off 
50,797 18.0 0.095 0.257 0.136 0.092 0.099 0.050 0.887 0.174 
Rapid Drop-off 22,404 7.9 0.267 0.385 0.318 0.093 0.281 0.064 0.856 0.177 
Gradual Drop-off 39,953 14.1 0.629 0.258 0.708 0.137 0.636 0.135 0.855 0.169 
Partial Drop-off 29,429 10.4 0.346 0.226 0.465 0.147 0.352 0.118 0.865 0.161 
Early Drop-off 
then Rebound 
28,304 10.0 0.733 0.196 0.789 0.100 0.720 0.100 0.818 0.151 
Adherent  111,633 39.5 0.973 0.016 0.979 0.031 0.975 0.043 0.956 0.086 
Comparison of Adherence Measures Ability to Distinguish between Adherent and Non-Adherent 
Months 
Adherence 
Measure AUCc 95% Confidence Interval (CI) 
PDC 0.914 0.914, 0.914 
PMC 0.918 0.918, 0.919 
Trajectory Model 0.954 0.954, 0.955 
a Average probability of being at least 80% adherent over 12 months of follow-up. 
b Indicates how well beneficiaries fit in their assigned group. 0.70 is typically used as a threshold to 
signify good model fit. 
c Area under the curve (AUC) statistics are used to quantify the ability of the measures to discriminate 
between adherent and non-adherent months. Values of 1 symbolize perfect discrimination.   
Overall model BIC for 6-group trajectory model: -1300277. 
BIC= Bayesian information criterion. BIC is used as a measure of model fit. Lower BIC values signify 
better model fit. 
Logistic regression models were used to identify trajectory groups. The dependent variables were the 
monthly binary indicators of antihypertensive use and months since start of antihypertensive therapy 
were the independent variables. Time was modeled using cubic terms. 
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Table 5: Distribution of baseline characteristics according to adherence trajectory among Medicare beneficiaries initiating 
antihypertensives 
 Trajectory Group, n % 
Covariates 
Immediate 
Dropoff 
Rapid 
 Dropoff 
Gradual  
Dropoff 
Partial  
Dropoff 
Early 
Dropoff then 
Rebound Adherent  
 n= 50,797 n=22,404 n=39,953 n=29,429 n=28,304 n=111,633 
Female Gender 59.9 57.3 58.9 59.8 61.1 60.8 
Mean Age (std) 75.3 (7.1) 75.0 (7.0) 75.0 (7.0) 75.1 (7.0) 75.2 (7.1) 75.0 (7.1) 
White Race  80.8 82.2 83.6 77.9 83.4 88.6 
Initiated with Combination Therapy 8.7 12.1 13.6 11.8 13.5 17.7 
Average Days Supply on Index Date 
(std) 27.3 (9.0) 40.6 (25.9) 35.1 (21.9) 29.6 (15.1) 30.6 (17.5) 32.6 (19.7) 
Medication Use 14 Days Prior to Index 
Date             
1-2 Meds 55.0 56.0 55.6 57.0 55.3 53.5 
3-4 Meds 30.1 29.3 28.9 29.1 29.1 29.1 
5 or More Meds 15.0 14.7 15.5 13.9 15.5 17.3 
Insurance Gap During Baseline 16.0 15.7 16.4 14.5 16.5 16.7 
Eligible for Low-Income Subsidy 5.6 5.3 5.6 6.1 5.7 5.6 
Loop Diuretic  9.5 9.6 10.4 9.4 10.7 11.1 
Antiarrhythmic 5.2 4.5 4.5 4.7 4.8 4.6 
Antidepressanta 17.4 17.1 17.7 16.5 17.8 16.8 
Antiepileptic 10.5 10.1 9.6 9.2 10.2 9.1 
Anxiolytic 4.9 4.4 4.2 4.4 4.1 3.7 
Benzodiazepine 1.5 1.3 1.3 1.2 1.2 1.2 
Opioid 37.1 33.2 33.0 34.2 34.0 30.2 
Hypnotic 8.5 8.0 7.3 7.5 7.7 6.7 
Diabetes 24.8 28.3 27.6 28.3 28.6 25.5 
Chronic Kidney Disease 11.9 11.8 12.0 11.8 12.4 11.5 
Parkinson's Disease 2.0 1.7 1.7 1.5 1.7 1.5 
Alzheimer’s Disease 3.3 2.8 3.3 2.7 3.3 3.5 
COPD 19.5 17.3 17.5 17.3 17.7 16.4 
Congestive Heart Failure 10.1 9.8 10.7 9.9 10.6 11.5 
Arrhythmia 20.9 20.5 20.9 18.3 20.4 23.4 
Osteoarthritis 18.7 18.0 17.5 18.5 18.2 16.1 
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Rheumatoid Arthritis 3.8 3.5 3.5 3.8 3.5 3.1 
Stroke 16.1 15.9 16.1 15.2 16.8 16.6 
Myocardial Infarction 1.8 2.0 2.4 1.5 2.1 3.8 
Hypertension 66.4 73.2 77.8 74.6 79.1 79.6 
Obesity 4.6 4.8 5.0 4.8 5.3 5.0 
Fracture History 9.8 8.2 8.4 8.8 8.7 7.9 
Average Frailty Predictor Index (std)b 0.11 (0.1) 0.10 (0.1) 0.10 (0.1) 0.10 (0.1) 0.11 (0.1) 0.10 (0.1) 
Home Oxygen Use 5.1 4.5 4.2 4.3 4.4 4.1 
Walker or wheelchair use 4.5 4.0 3.9 4.2 4.2 3.8 
Hospital Bed 1.2 0.8 1.0 1.0 1.0 0.9 
Difficulty Walking 11.4 10.6 10.5 10.4 11.0 10.3 
Vertigo 15.9 14.6 13.7 14.5 14.0 12.7 
Ambulance Transport 14.8 11.8 12.6 11.7 12.9 13.7 
Cancer Screenings 34.6 35.5 37.3 34.8 37.7 39.5 
Hospital Admissions 25.2 21.2 21.5 19.6 21.7 23.8 
Long Stay Admissions 2.1 1.5 1.6 1.5 1.8 1.8 
Short Term Hospital Stays 24.3 20.6 20.8 18.8 20.8 23.0 
a Antidepressants include selective serotonin reuptake inhibitors, tricyclics, monoamine oxidase inhibitors, serotonin and 
norepinephrine inhibitors 
b Higher scores denote a higher probability of being frail 
std=standard deviation 
Index date= start of antihypertensive therapy 
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Table 6: Strongest predictors of antihypertensive non-adherence trajectories among Medicare beneficiaries initiating antihypertensive therapy 
 Patterns of Adherence 
  Odds Ratios (ORs) and 95% Confidence Intervals (CIs) 
  
Immediate  
Drop-off 
Rapid 
 Drop-off 
Gradual  
Drop-off 
Partial  
Drop-off 
Early Drop-off 
then Rebound Adherent  
Initiation with Monotherapya 2.08 (2.00, 2.13) 1.49 (1.43, 1.56) 1.33 (1.28, 1.37) 1.52 (1.45, 1.59) 1.32 (1.25, 1.35) 1 
Non-White Race 2.05 (1.99, 2.12) 1.85 (1.78, 1.93) 1.59 (1.54, 1.64) 2.26 (2.19, 2.34) 1.58 (1.52, 1.64) 1 
Hypertension 2.04 (2.00, 2.08) 1.49 (1.45, 1.56) 1.15 (1.12, 1.19) 1.41 (1.37, 1.45) 1.08 (1.04, 1.11) 1 
No History of Myocardial 
Infarction 2.00 (1.85, 2.17) 1.52 (0.60, 0.74) 1.28 (1.19, 1.39) 1.92 (1.72, 2.13) 1.49 (1.35, 1.64) 1 
Frailty Predictor Index 1.47 (1.32, 1.64) 1.37 (1.18, 1.61) 1.18 (1.04, 1.33) 1.72 (1.49, 2.00) 1.37 (1.19, 1.56) 1 
Parkinson's Disease 1.40 (1.29, 1.53) 1.31 (1.16, 1.48) 1.20 (1.09, 1.32) 1.19 (1.07, 1.34) 1.21 (1.08, 1.35) 1 
No History of Arrhythmia 1.30 (1.25, 1.33) 1.15 (1.10, 1.19) 1.14 (1.10, 1.16) 1.32 (1.27, 1.35) 1.18 (1.14, 1.22) 1 
Opioid Use 1.33 (1.30, 1.36) 1.18 (1.14, 1.22) 1.16 (1.13, 1.19) 1.26 (1.22, 1.29) 1.19 (1.15, 1.22) 1 
No History of  Being In The 
Insurance Gap 1.25 (1.22, 1.30) 1.14 (1.09, 1.19 ) 1.09 (1.04, 1.12) 1.27 (1.22, 1.32) 1.12 (1.08, 1.16) 1 
Vertigo 1.25 (1.21, 1.29) 1.20 (1.15. 1.26) 1.10 (1.06, 1.14) 1.17 (1.12, 1.21) 1.08 (1.04, 1.12) 1 
COPD 1.24 (1.20, 1.28) 1.15 (1.10, 1.20) 1.15 (1.11, 1.19) 1.17 (1.13, 1.22) 1.14 (1.10, 1.18) 1 
Prior Medication Use       
1-2 Meds ref ref ref ref ref ref 
3-4 meds 1.04 (1.01, 1.06) 1.03 (1.00, 1.08) 1.06 (1.03, 1.09) 1.08 (1.05, 1.11) 1.06 (1.03, 1.10) 1 
≥ 5 meds 1.23 (1.19, 1.28) 1.15 (1.10, 1.20) 1.16 (1.11, 1.20) 1.30 (1.23, 1.35) 1.19 (1.14, 1.25) 1 
No History of Hospital 
Admissions 1.23 (1.05, 1.45) 1.45 (1.14, 1.85) 1.22 (1.02, 1.47) 1.19 (0.96, 1.47) 1.20 (0.98, 1.47) 1 
a Initiated with one class of antihypertensive drug vs. more than one class of antihypertensive drugs. We did not distinguish between single pill 
combination therapy medications.  
Odds Ratios and 95% CIs are adjusted for all baseline covariates. ORs > 1 are predictive of non-adherence.  
AUC-statistic for fully adjusted model: 0.525 
Only the strongest predictors of non-adherence are shown, see Table 23 in the Appendix for full listing of baseline covariates. Prevalence of 
baseline characteristics were assessed in the 12 months prior to initiation.  
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Table 7: Influence of prior statin persistence on antihypertensive adherence trajectories following initiation of antihypertensive therapy 
 Trajectory Group (n, %) 
Statin Persist Sub-
Cohort (n=69,668) 
Immediate  
Drop-off 
Rapid  
Drop-off 
Gradual  
Drop-off 
Partial  
Drop-off 
Early Drop-off 
then Rebound Adherent 
Persistent ≥ 180 days 
(n=47,668) 6,727 14.1 3,295 6.9 6,517 13.7 3,781 7.9 4,759 10.0 22,589 47.4 
Not persistent at least 
180 days (n=22,000) 4,215 19.2 2,003 9.1 3,501 15.9 2,973 13.5 2,454 11.2 6,854 31.2 
Baseline Prediction Model + Prior Statin 
Persistence          
Odds Ratio (95% CI)a 0.48 (0.46, 0.50) 0.49 (0.46, 0.53) 0.56 (0.54, 0.59) 0.40 (0.37, 0.42) 0.60 (0.57, 0.64) Referent 
AUC-statistic adjusted for all covariates and  prior statin persistence: 0.531 
a Odds ratio comparing prior statin persistence and the odds of belonging to the no drop-off group. Adjusted for all baseline covariates. 
ORs < 1 are predictive of being more adherent.  
CI= confidence interval 
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Figure 2: Eligibility flow chart for the study cohort 
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Figure 3: Antihypertensive adherence trajectories in the 12 months following initiation 
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CHAPTER 5: INITIATION OF ANTIHYPERTENSIVE MONOTHERAPY AND INCIDENT 
FRACTURES AMONG MEDICARE BENEFICIARIES 
5.1 Introduction 
Fractures are one of the most common fall-related injuries for adults over the age of 65.89  In 
older adults, fractures are associated with high medical costs, loss of independence, and an increased risk 
of mortality.43-45,90 Older adults are at greater risk of fractures due to decreased bone mineral density 
(BMD), increased comorbidities, and increased medication use.30,91  Comorbidities such as cardiovascular 
disease, osteoporosis, Parkinson’s disease, and diabetes can increase fracture risk.30,52,92  Medications 
increasing the risk of fractures include opioids, benzodiazepines, antidepressants, antiepileptics, and 
skeletal muscle relaxants.65,93,94  Recently, research suggests antihypertensives may increase the risk of 
fall-related injury by as much as 11% among older adults.11,60   
Antihypertensives are associated with fractures through medication-related adverse events and by 
interactions with BMD.12  First, antihypertensives can increase the risk of falls and subsequent fractures 
upon initiation due to orthostatic hypotension.11,30  Orthostatic hypotension is defined as a decrease in 
blood pressure upon standing,68 and is associated with an elevated risk of falls and fractures among 
hypertensive adults.95  Second, antihypertensives have been suggested to impact BMD in observational 
and clinical studies. For instance, thiazide diuretics reduce urinary calcium secretion and can stimulate 
osteoblasts potentially providing a protective effect for fractures.32,67,96  Angiotensin receptor blockers and 
angiotensin converting enzyme inhibitors are believed to impact BMD by inhibiting bone turnover caused 
by the renin-angiotensin-aldosterone system.32   
Prior research has found inconsistent results regarding the strength and direction of the 
association between antihypertensives and fractures.11,66   Some studies have found antihypertensives 
increase the risk of fractures60,61,97, while others have found no association65, or a protective association 
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for fractures.67,96,98  Few studies have examined the initial increased risk of fractures associated with 
starting antihypertensive therapy, and how the association between antihypertensives and fractures varies 
time. Therefore, we sought to examine the association between antihypertensives and incident non-
vertebral fractures within the first year of initiation among Medicare beneficiaries. We hypothesized that 
the association between antihypertensives and fractures would vary over time due to different time-
dependent drug effects.  
5.2 Methods  
Data Source 
We used a 20% nationwide, random sample of fee-for-service Medicare beneficiaries who were 
enrolled at least one month in  Medicare Parts A (inpatient care), B (outpatient care), and D (prescription 
drugs) coverage between 2007 and 2011. Data were obtained under a data use agreement established with 
the Centers for Medicaid and Medicare Services (CMS) and the University of North Carolina at Chapel 
Hill (UNC-CH). The study protocol was approved by UNC’s Non-Biomedical Institutional Review 
Board.  
New Users of Antihypertensive Monotherapy 
The study cohort consisted of all new users of antihypertensive medication initiating during 2008-
2011 who were continuously enrolled in Medicare Parts A, B, and D for at least twelve months prior to 
initiation. New use was defined as not having a prior prescription of the following antihypertensive 
medications in the last twelve months: angiotensin converting enzyme inhibitors (ACE), angiotensin 
receptor blockers (ARB), beta blockers (BB), calcium channel blockers (CCB), or thiazide diuretics 
(THZ).  We limited the cohort to beneficiaries initiating with monotherapy (e.g., one class of 
antihypertensive drug) since we were interested in examining differences in effect by drug class.  
We excluded beneficiaries who were originally eligible for Medicare due to end stage renal 
disease or disability and those beneficiaries with prior nursing home stays.  Additionally, we excluded 
beneficiaries who had a previous diagnoses for tremor disorder or congestive heart failure since these 
health conditions could result in being prescribed antihypertensives.  Since we were interested in 
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capturing incident fractures, we excluded beneficiaries who had prior falls or fractures. Finally, we 
required a second antihypertensive fill within 30 days of the end of the index drug’s days supply to 
exclude those beneficiaries who filled the first prescription and never returned (Appendix Figure 10). We 
did not exclude beneficiaries with chronic kidney disease or diabetes, despite these being indications for 
certain antihypertensive drug classes, however we did conduct sub-analysis excluding these beneficiaries 
(see Statistical Analysis).  
Initiation of Antihypertensive Therapy 
Prescription medication data were identified using Medicare Part D. Using fill dates, we 
identified the date of the initial prescription for antihypertensive therapy (index date). Antihypertensive 
medications were identified using National Drug Codes (NDC) and generic drug names (Appendix Table 
18).  These specific drug classes were chosen based on the current recommendations for hypertension 
treatment in older adults.13   
Incident Non-Vertebral Fractures 
Incident non-vertebral fractures within twelve months of initiating antihypertensive monotherapy 
were our primary outcome. Starting the day after the index date, we followed beneficiaries until the first 
fracture event. Fractures were identified using validated diagnostic and procedure codes in Medicare Parts 
A and B (Appendix Table 23).99 We chose to examine fractures instead of falls since the accuracy of fall 
reporting varies by state and has low specificity in claims data.100 We excluded fractures that had a 
corresponding external cause-of-injury relating to motor vehicle crashes (E810-E825) and those that 
occurred on the index date. 
In sub-analyses, we grouped fractures according to the anatomical location to distinguish between 
fractures that were likely related to low BMD.  Low BMD fractures, or osteoporotic fractures, are 
typically defined as fractures occurring at the hip, radius, or vertebrae.53  Since incident vertebral fractures 
are not well captured in claims data101, we defined probable low BMD fractures as any fracture event 
involving the hip or radius.53  All other non-vertebral fracture were classified as probable normal BMD 
fractures.  
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Risk Factors for Fractures 
Covariates were selected based on the previous literature 30,92,93,102-104 and were defined based on 
claims during the twelve months prior to initiation (Appendix Table 24). Covariates included: 
demographics (age, gender, and race), concurrent medication use and prior use of medications associated 
with fractures (loop diuretics, antiarrhythmics, antidepressants, antiepileptics, anxiolytics, 
benzodiazepines, bisphosphonates, antipsychotics, skeletal muscle relaxants,  opioids, and hypnotics), 
codes for chronic comorbidities associated with fracture risk (diabetes, chronic kidney disease, 
Parkinson’s disease, Alzheimer’s disease, osteoporosis, arrhythmia, osteoarthritis, rheumatoid arthritis, 
stroke, myocardial infarction, hypertension, orthostatic hypotension, syncope, dementia, urinary 
incontinence, dyslipidemia, and obesity), frailty predictors, and prior hospital utilizations (hospital 
admissions).  Concurrent medication use was defined as the number of distinct drug prescriptions filled in 
the 14 days prior to antihypertensive initiation.  As a proxy for sociodemographic status, we identified 
whether beneficiaries were eligible for the Medicare low-income subsidy (LIS) program. LIS offers 
medication at a reduced cost for beneficiaries that are eligible due to income, family size, and household 
resources.  We included the frailty index score (FIS) as a proxy measure of frailty.76  Additionally, we 
examined the prevalence of factors positively (ambulance transfer, wheelchair/walker use, home oxygen 
use, hospital bed, difficulty walking, and vertigo) and inversely (cancer screenings) associated with 
limitations in activities of daily living.76  
Statistical Analysis 
Descriptive statistics were used to compare baseline covariates according to antihypertensive 
class initiated on the index date. We estimated propensity scores using multinomial logistic regression 
models to adjust for differences in the distribution of baseline covariates across antihypertensive drug 
classes. Standardized mortality ratio (SMR) weighting was used to weight beneficiaries of each drug class 
to achieve the same baseline covariate distribution as beneficiaries receiving an ACE. Therefore, 
beneficiaries initiating with ACEs were assigned a weight of one and all others were assigned a weight 
that was the ratio of the propensity score to one minus the propensity score.105  ACEs were used as the 
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referent since they were the most commonly prescribed drug class.106  To assess the effectiveness of the 
propensity scores, we examined the distribution of baseline covariates after SMR weighting.   
Incident fracture rates and corresponding 95% confidence intervals (CIs) were defined as the total 
number of incident fractures by the total person-years at risk.  Person-years was defined as the total 
number of days at risk for fractures divided by 365.25. We used SMR-weighted Cox proportional hazard 
models to estimate hazard ratios (HRs) and 95% CIs of incident fractures for each drug class initiated on 
the index date versus receiving an ACE according to days since initiation of therapy, 1-14 days and 15-
365 days. CIs were calculated using robust standard errors to account for SMR weights. We used a ‘first-
treatment-carried-forward’ analysis to avoid introducing confounding by indication since antihypertensive 
adherence varies, and beneficiaries who remain adherent may differ from the majority of hypertensive 
patients.107  Using this analysis, beneficiaries contributed person-time at risk until they had an incident 
fracture or until the end of the follow-up (death, disenrollment from Medicare, or December 31, 2012), 
whichever came first. SMR weighted Kaplan-Meier curves were used to graph the proportion of 
beneficiaries without fracture events according to time since initiation. For our secondary analysis when 
we classified fractures according to probable low vs. normal BMD fractures, if a beneficiary had a 
fracture event before the event of interest (e.g., normal BMD fracture before a low BMD fracture), 
beneficiaries were censored at the date of the first fracture event.  
Sensitivity Analyses 
To assess the robustness of our analysis decisions, we performed four separate sensitivity 
analyses. First, we repeated the analysis using an ‘As-treated’ design.  In the ‘As-treated’ analysis, 
follow-up additionally ended when beneficiaries switched antihypertensive therapy (e.g., switched to 
another antihypertensive class or started combination therapy), or discontinued use (e.g., failed to fill 
another prescription 30 days after the end of the last drugs’ days supply). Second, we repeated the 
analysis extending the first follow-up period to 30 days since the time it takes for blood pressure to 
stabilize after antihypertensive initiation is not known. Third, we repeated the primary analysis excluding 
beneficiaries who initiated therapy using a brand antihypertensive medication versus a generic 
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antihypertensive medication. Generic medications are less prone to sample use and are thus less prone to 
have started antihypertensive therapy before the first dispensed prescription.87  Lastly, since chronic 
kidney disease and diabetes can impact physicians’ choice of antihypertensive class prescribed, we 
repeated the analysis removing any beneficiaries with these chronic conditions.  
5.3 Results 
Between 2008 and 2011, 122,629 Medicare beneficiaries initiated antihypertensive monotherapy. 
On average beneficiaries were 75 years old, 61% were women, and the majority were White (86%). The 
most common classes of antihypertensives prescribed were ACEs (33%), BBs (30%), and CCBs (15%).  
Before SMR weighting, demographics, diabetes, chronic kidney disease, cardiovascular disease (e.g., 
arrhythmia, stroke, hypertension, and dyslipidemia), ambulance transfers, cancer screenings, and prior 
hospitalizations differed across beneficiaries according to antihypertensive class.  After SMR weighting, 
there was little difference between baseline characteristics according to antihypertensive class (Table 8).  
During the first year after initiation of antihypertensive monotherapy, beneficiaries experienced 
4,430 incident non-vertebral fractures over 115,991 person-years (rate = 382 per 10,000 person-years, 
95%CI: 371-393). Fractures most commonly occurred at the hip (79%), foot (17%), radius (15%), and 
hand (14%).  Just over one-third of the fractures resulted in a single-bone break (77%). 
Rates of incident fracture varied according to antihypertensive class and by time since initiation 
(Table 9, Appendix Figure 11). During the first 14 days, beneficiaries who initiated with THZs (438 per 
10,000 person-years, 95%CI: 294-628) and BBs (410 per 10,000 person-years, 95%CI: 314-526) had the 
highest rate of fractures. Beneficiaries initiating with CCBs had the highest rate of fractures during the 
15-365 days after initiation (435 per 10,000 person-years, 95%CI: 404-468), but a low rate in the first 14 
days (383 per 10,000 person-years, 95%CI: 258-550). Initiators of ARBs had the lowest rate of fractures 
during the initial 14 days (333 per 10,000 person-years, 95%CI: 190-546) and during the 15-365 days 
after initiation (321 per 10,000 person-years, 95%CI: 287-358).  
After controlling for differences in baseline characteristics, beneficiaries who initiated with THZs 
had the highest rate of fractures in the first 14 days after initiation compared to beneficiaries who initiated 
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with ACEs (SMR-HR: 1.40, 95%CI: 0.78-2.52). After the first 14 days, beneficiaries who initiated with 
CCBs (SMR-HR: 1.11, 95%CI: 1.00-1.24) and BBs (SMR-HR: 1.09, 95% CI: 1.00-1.19) had slightly 
higher fractures rates compared to the beneficiaries who initiated with ACEs.  
When we compared the rates of incident probable low BMD fractures and normal BMD fractures, 
results were similar for all the antihypertensive classes except THZs. During the one year following 
initiation, beneficiaries who initiated with THZs had a lower hazard ratio of probable low BMD fractures 
(SMR-HR: 0.85, 95%CI: 0.68-1.06), but a slightly higher hazard ratio of normal BMD fractures (SMR-
HR: 1.12, 95%CI: 0.98-1.29) compared to beneficiaries who initiated with ACEs (Table 10).  
In sensitivity analyses, results were similar when we 1) used an ‘as-treated’ analysis, 2) excluded 
beneficiaries with a previous diagnosis of chronic kidney disease or diabetes, and 3) excluded 
beneficiaries who initiated with brand antihypertensive drugs (Figure 4, Appendix Table 25). When we 
extended the initial follow-up period to 30 days, beneficiaries who initiated with THZs (SMR-HR: 1.15, 
95%CI: 0.75-1.76) and BBs (SMR-HR: 1.36, 95%CI: 1.01-1.83) still had the highest rate of fractures 
compared to beneficiaries who initiated with other antihypertensive classes (results not shown).  
5.4 Discussion 
We found incident fracture rates in the year following initiation of antihypertensive therapy differ 
depending on antihypertensive class, and these patterns were affected by the time since initiation. 
Medicare beneficiaries who initiated with THZs or BBs had higher fracture rates during the first two 
weeks compared to beneficiaries who initiated with other antihypertensives. However, during the first 
year beneficiaries who initiated with CCBs had the highest fracture rate.  Similar to previous research, we 
found beneficiaries who initiated with ACEs or ARBs had the lowest rate of fractures.11,61,108   
We found older adults initiating with THZs or BBs had the highest fracture rates during the first 
two weeks following initiation.  Similar to our results, Berry et al. found that THZs initiators had an 
increased odds of hip fracture in the first days following initiation compared to periods of no use.109  Butt 
et al. found that the use of any antihypertensive was associated with an increased risk of hip fracture in 
the first 45 days following initiation, and that this risk was most elevated for older adults initiating with 
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ACEs.63  However, Ruths et al. found that only loop diuretics were associated with an initial increased 
risk of hip fractures during the first two weeks of use when comparing the initial fracture risk among 
antihypertensive classes.67  The initial increase in fracture rates may be due to orthostatic hypotension. 
Among the classes of antihypertensives, THZs and BBs are most strongly associated with orthostatic 
hypotension.30  Given that orthostatic hypotension can be asymptomatic,11,110 results suggest that 
clinicians and older adults need to be aware of the potential increased risk of orthostatic hypotension and 
subsequent fractures upon initiation, especially when starting with THZs or BBs.    
Gangavati et al. found that the risk of falls associated with orthostatic hypotension was lower 
among older adults with controlled hypertension compared to older adults with uncontrolled 
hypertension.95  This suggests that increases in fracture rates once hypertension is controlled are due to 
other mechanisms besides orthostatic hypotension. One mechanism that may influence the association 
between antihypertensives and fractures could be antihypertensives interactions with BMD.12,32  We 
found older adults initiating with THZs had a decreased rate of hip and radius fractures in the year 
following initiation. THZs can impact the risk of low BMD fractures by promoting osteoblast activity and 
reducing calcium urinary excretion.32,111  A 2011 Cochrane review found that THZs were associated with 
as much as a  24% reduction in hip fractures when comparing THZ users vs. non-users.111  Results 
suggest that older adults at elevated risk of fractures may potentially benefit from receiving THZs 
compared to other classes of antihypertensives. However, we were unable to clinically measure BMD.  
More research is needed featuring clinical BMD measurements to see if these results hold in clinical 
settings.  
Older adults initiating with CCBs had higher fracture rates compared with ACE initiators. 
Previous studies have found inconsistent results regarding the association between CCBs and fractures.  
Ruths et al. found that CCBs were associated with a decreased risk of hip fractures when comparing 
periods of use and non-use.67  However, this study was limited to hip fractures and results were 
unadjusted for comorbidities associated with fractures.67  In another study, Choi et al. found that 
compared to non-users of antihypertensives, adults prescribed CCBs had a slightly elevated rate of non-
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vertebral fractures.61  In our study, beneficiaries who initiated with CCBs were frailer than beneficiaries 
who initiated with other antihypertensives. Although we included frailty predictors in the propensity 
scores, we cannot eliminate the possibility that residual confounding remained after adjustment, given 
that frailty is multi-dimensional and is difficult to capture with claims data alone.112   
Despite conducting sensitivity analyses, this study does have limitations. First, results may be 
subject to residual confounding. We used SMR weights to limit confounding by indication but were 
unable to control for physical activity, visual impairment, baseline BMD, and alcohol use. Some research 
suggests removing outlier SMR weights to better control for residual confounding. We did not exclude 
outlier weights since excluding these observations resulted in little difference in the results, suggesting 
that variations in weights were most likely random. Second, our study population was predominantly 
White. It is unknown if these results would hold true for non-White populations. Third, our results are 
limited to the one year period following initiation. The time it takes for antihypertensives to have 
clinically relevant BMD affects are not known. One year may not have been long enough to identify all 
possible BMD affects. Lastly, our results did not take into account antihypertensive dose. Previous 
research suggests that the relationship between antihypertensives and fractures is linearly associated with 
increasing dose.11,64  Results may be underestimated for older adults on higher doses of antihypertensives.  
It is important that researchers and clinicians identify modifiable factors that can reduce the risk 
of fractures among older adults.  We found certain classes of antihypertensive medications may impact 
the rate of fractures in older adults. Specifically, THZs and BBs were associated with increased fracture 
rates in the first two weeks after initiation. Older adults taking these medications should be aware of this 
possible increased risk of fractures, particularly in the first few weeks after starting therapy. Also, we 
found that ACEs and ARBs are associated with lower fracture rates after initiation. When deciding upon 
antihypertensive therapy, clinicians may want to consider different fracture risks when choosing between 
antihypertensive drug classes, especially in frail older adults or those with a history of falls or fractures.  
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Table 8: Characteristics of  Medicare beneficiaries initiating antihypertensive monotherapy between 2008-2011 
(n=122,629) 
 
ACE 
n=40,186 
ARB  
n=10,954 
BB 
 n=36,972 
CCB   
n=18,411 
THZ 
  n=16,106 
 Cohort  Cohort SMRW Cohort SMRW Cohort SMRW Cohort SMRW 
Mean Age, std (years) 74, 6.7 75, 6.7 74, 12.9 75, 7.0 74, 7.1 76, 7.4 75, 10.0 75, 7.0 75, 10.8 
Mean Frailty Index, std 0.1, 0.1 0.1, 0.1 0.1, 0.2 0.1, 0.1 0.1, 0.1 0.1, 0.2 0.1, 0.2 0.1, 0.1 0.1, 0.2 
Male, % 42.0 36.6 41.5 41.7 42.2 37.8 42.1 29.3 42.4 
White  Race, % 87.1 79.1 87.3 89.0 86.9 81.9 86.9 86.5 87.1 
Low-Income Subsidy, %  5.3 5.5 5.5 4.6 5.4 5.8 5.4 5.1 5.2 
Medication History, %          
1-2 Meds Filleda 61.3 62.4 61.8 58.6 61.4 59.8 62.5 66.9 62.5 
3-4 Meds Filleda 27.7 26.5 27.4 28.7 27.2 27.1 26.3 24.7 26.5 
5 + Meds Filleda 11.1 11.2 10.8 12.7 11.4 13.0 11.3 8.5 11.1 
Loop Diuretic  5.8 5.9 5.9 7.0 6.1 6.4 6.0 3.7 6.4 
Antiarrhythmic 2.6 4.2 2.5 5.4 2.8 4.5 2.7 2.7 3.0 
Antidepressantb 15.2 14.9 15.2 16.0 15.6 15.9 15.6 15.4 15.5 
Antipilepticb 7.4 7.3 7.3 8.0 7.5 8.2 7.6 7.7 7.4 
Anxiolytic 3.4 3.4 3.5 4.0 3.6 4.1 3.6 3.7 3.5 
Benzodiazpeneb 1.1 1.0 1.1 1.5 1.2 1.3 1.2 1.3 1.1 
Bisphosphonate 10.6 12.4 10.6 11.2 10.4 11.6 10.7 13.0 10.8 
Antipsychoticb 3.5 2.8 3.5 4.2 3.7 4.9 3.7 3.8 3.7 
Skeletal Muscle 
Relaxantb 6.2 6.2 6.2 6.5 6.5 6.3 6.4 6.5 6.4 
Opioid 27.0 26.2 27.4 30.2 27.2 29.5 27.5 28.0 28.2 
Hypnoticb 6.1 7.9 6.0 7.5 6.1 7.14 6.2 6.7 6.2 
Chronic Conditions, %          
Diabetes 31.6 30.6 31.0 19.0 32.8 18.3 31.4 13.5 32.9 
Chronic Kidney 
Disease 8.7 10.5 8.8 10.6 9.4 13.1 9.3 6.3 9.8 
Parkinson's Disease 1.2 1.1 1.2 1.5 1.2 1.5 1.2 1.3 1.2 
Alzheimer's Disease 3.2 2.4 3.1 3.0 3.4 4.4 3.3 3.1 3.6 
Osteoporosis 14.1 17.3 14.2 16.0 14.1 17.4 14.4 16.9 14.6 
Arrhythmia 10.5 10.9 10.4 32.9 10.6 25.4 10.6 8.5 11.6 
Osteoarthritis 14.4 17.8 14.3 16.1 14.7 15.5 14.9 15.7 15.1 
Rheumatoid Arthritis 2.5 3.4 2.5 3.2 2.6 3.0 2.7 2.5 2.6 
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Stroke 13.7 13.5 13.5 16.6 15.0 16.4 15.1 10.3 14.9 
Myocardial Infarction 0.6 0.2 0.6 4.0 0.6 0.6 0.7 0.1 0.7 
Hypertension 83.3 88.2 83.5 63.3 84.3 78.6 85.3 76.8 85.0 
Orthostatic 
Hypotension 0.6 0.6 0.7 1.1 0.7 0.9 0.8 0.5 0.6 
Syncope 3.8 4.2 3.7 7.4 4.0 6.1 4.2 3.0 4.3 
Dementia 5.8 4.2 5.6 5.9 6.1 8.2 6.1 5.6 6.1 
Urinary Incontinence 4.7 4.8 4.7 4.9 4.8 5.5 4.9 4.5 4.9 
Dyslipidemia 64.8 70.2 64.2 64.0 65.7 58.2 65.3 57.2 65.3 
Obesity 4.4 4.2 4.5 3.7 4.6 3.3 4.4 4.1 4.4 
Frailty Indicators, %          
Home Oxygen Use 2.4 2.5 2.4 2.5 2.6 5.3 2.3 2.7 2.6 
Walker/Wheelchair Use  2.2 2.4 2.2 2.8 2.3 3.3 2.3 2.4 2.5 
Hospital Bed Use 0.5 0.5 0.5 0.5 0.5 0.9 0.5 0.5 0.6 
Difficulty Walking 7.7 7.5 7.6 8.9 8.2 9.5 8.4 8.2 8.3 
Vertigo 11.5 12.4 11.3 14.5 12.1 14.1 12.4 12.4 12.1 
Ambulance Transport 6.9 4.8 6.8 12.4 7.3 12.6 7.3 5.4 7.5 
Cancer Screenings 41.0 39.2 40.9 39.3 40.4 35.5 40.6 43.7 40.1 
Hospital Utilization, %          
Hospital Admissions 13.2 10.1 13.2 25.5 13.6 23.8 13.3 10.1 14.3 
a Number of number of distinct drug prescriptions filled in the 14 days prior to antihypertensive initiation 
b Medication indicated to be associated with fracture risk according to the 2015 Beers Medication Guideline.93 
Prevalence of baseline characteristics was identified 12 months prior to initiation of antihypertensive monotherapy. 
Race was missing for a total of 147 beneficiaries and these were excluded from the SMR weighted analysis 
SMRW= standardized mortality ratio weighting (ACE was the referent). Angiotensin converting enzyme inhibitors (ACE), 
angiotensin receptor blockers (ARB), beta blockers (BB), calcium channel blockers (CCB), or thiazide diuretics (THZ) 
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Table 9: Rates and adjusted hazard ratios (HRs) of incident non-vertebral fractures within the first year of initiation among 
Medicare beneficiaries starting antihypertensive monotherapy 
  1-14 days after initiation 15-365 days after initiation 
Drug 
Class 
# 
Fractures 
P-
Yrs 
Rate Per 10,000  
P-Yrs (95% CI)  
 SMRW HR  
(95% CI) 
# 
Fractures P-Yrs 
Rate Per 
10,000  P-Yrs 
(95% CI) 
 SMRW HR 
 (95% CI) 
ACE 54 1,539 351 (266, 454) ref 1,271 36,618 347 (328, 367) ref 
ARB 14 420 333 (190, 546) 0.92 (0.49, 1.75) 322 10,032 321 (287, 358) 0.96 (0.84, 1.09) 
BB 58 1,416 410 (314, 526) 1.00 (0.65, 1.54) 1,375 33,449 411 (390, 433) 1.09 (1.00, 1.19) 
CCB 27 705 383 (258, 550) 0.82 (0.50, 1.36) 720 16,540 435 (404, 468) 1.11 (1.00, 1.24) 
THZ 27 617 438 (294, 628) 1.40 (0.78, 2.52) 562 14,656 384 (353, 416) 1.02 (0.90, 1.15) 
P-Yrs= person-years (calculated by dividing the total number of follow-up days by 365.25) 
SMRW= Standardized mortality ratio weight, calculated adjusting for all baseline covariates.  
HRs and 95% confidence intervals (CIs) are adjusted for SMRWs. 
Angiotensin converting enzyme inhibitors (ACE), angiotensin receptor blockers (ARB), beta blockers (BB), calcium 
channel blockers (CCB), or thiazide diuretics (THZ) 
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Table 10: Rates and hazard ratios (HRs) of incident probable low and normal bone mineral density (BMD) fractures within the 
first year of initiation among Medicare beneficiaries starting antihypertensive monotherapy 
   Probable Low BMD Fractures Normal BMD Fractures 
Drug 
Class 
# 
Fractures P-Yrs 
Rate Per 10,000  
P-Yrs (95% CI)  
 SMRW HR  
(95% CI) 
# 
Fractures P-Yrs 
Rate Per 
10,000  P-Yrs 
(95% CI) 
 SMRW HR  
(95% CI) 
ACE 424 38,157 111 (101, 122) ref 901 38,157 236 (221, 252) ref 
ARB 99 10,452 95 (77, 115) 0.93 (0.74, 1.17) 237 10,452 227 (199, 257) 0.97 (0.84, 1.13) 
BB 464 34,864 133 (121, 146) 1.08 (0.93, 1.26) 969 34,864 278 (261, 296) 1.09 (0.98, 1.21) 
CCB 280 17,245 162 (144, 182) 1.13 (0.95, 1.35) 467 17,245 271 (274, 296) 1.09 (0.96, 1.24) 
THZ 171 15,273 112 (96, 130) 0.85 (0.68, 1.06) 418 15,273 274 (248, 301) 1.12 (0.98, 1.29) 
P-Yrs= person-years (calculated by dividing the total number of follow-up days by 365.25). 
SMRW= Standardized mortality ratio weight, calculated adjusting for all baseline covariates.  
HRs and 95% confidence intervals (CIs) are adjusted for SMRWs. 
Probable low BMD fractures included hip and radius fractures. All other non-vertebral fractures were defined as normal BMD 
fractures.  
Angiotensin converting enzyme inhibitors (ACE), angiotensin receptor blockers (ARB), beta blockers (BB), calcium channel 
blockers (CCB), or thiazide diuretics (THZ). 
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Figure 4: Sensitivity analysis results for the adjusted hazard ratios comparing the rate of incident fractures after initiation of antihypertensive 
monotherapy according to criteria used to identify the Medicare cohort. The reference group for the SMR weights were Medicare beneficiaries 
initiating with angiotensin converting enzyme inhibitors.  
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CHAPTER 6: ANTIHYPERTENSIVE ADHERENCE TRAJECTORIES AND SUBSEQUENT 
FRACTURES 
6.1 Introduction 
Previous research has suggested antihypertensive medications are associated with fractures due to 
interactions with bone mineral density (BMD).11,32  For instance, thiazide diuretics reduce urinary calcium 
secretion and stimulate osteoblasts, or bone cells, potentially providing a protective effect for 
fractures.32,67,96  Angiotensin-receptor blockers (ARB) and angiotensin-converting-enzyme inhibitors 
(ACE) are believed to impact BMD and subsequent fracture risk by inhibiting bone turnover caused by 
the renin-angiotensin-aldosterone system (RAAS).32  However, prior research has found inconsistent 
results regarding the association between antihypertensives and fractures.11,66   Some studies have found 
antihypertensives increase fracture risk60,61,97, while others have found no association65, or a protective 
association for fractures.67,96,98    
One reason for the inconsistent results may be due to confounding introduced by antihypertensive 
adherence. Prior studies have found that antihypertensive adherence trajectories vary in the first year after 
initiation.107 Approximately half of older adults remain adherent to their antihypertensive medication in 
the year following initation.4  Failure to remain adherent can lead to an increased risk of cardiovascular 
disease, hospitalization, and mortality.23,40,70,71  Older adults are at greater risk of nonadherence due to 
polypharmacy and increased comorbidities.2  Female gender, low income, mental health disorders, non-
White race and cognitive impairment are associated with non-adherence. 2,4,5,34  
No prior study has examined the impact antihypertensive adherence has on the association 
between antihypertensives and fractures.   If antihypertensives have protective effects on BMD, then older 
adults who are more adherent to their antihypertensive medication would most benefit by these 
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interactions.  In this study, we sought to examine the association between antihypertensive adherence and 
subsequent fractures among Medicare beneficiaries initiating antihypertensive therapy.  
6.2 Methods 
Data Source 
We used a 20% nationwide, random sample of fee-for-service Medicare beneficiaries with at least 
one month of combined parts A (inpatient care), B (outpatient care), and D (prescription drugs) coverage 
between 2007 and 2011. Data were obtained under a data use agreement established with the Centers for 
Medicaid and Medicare Services (CMS) and the University of North Carolina at Chapel Hill (UNC-CH). 
The study protocol was approved by UNC’s Non-Biomedical Institutional Review Board.  
Medicare beneficiaries initiating antihypertensive therapy 
The study cohort consisted of Medicare beneficiaries initiating therapy with antihypertensive 
medications during 2008-2011 who were enrolled in Medicare Parts A, B, and D for at least 12 months 
prior to initiation. New use was defined as not having a prior prescription for any of the following 
antihypertensive medications in the last 12 months: angiotensin-converting-enzyme inhibitors (ACE), 
angiotensin-receptor blockers (ARB), beta blockers (BB), calcium channel blockers (CCB), or thiazide 
diuretics (THZ). Given the four-year window used for identifying new use, beneficiaries potentially could 
qualify as new users more than once, but we limited the cohort to first time qualification of new use.  
Beneficiaries who were originally eligible for Medicare due to end stage renal disease or 
disability and those who were less than 66 years of age at the start of therapy were excluded. We excluded 
beneficiaries with prior nursing home stays and those with a diagnosis of metastatic cancer in the year 
prior to starting therapy since these factors could impact adherence to chronic medication. Additionally, 
we excluded beneficiaries who had previous diagnoses for tremors or congestive heart failure since these 
health conditions could result in being prescribed antihypertensives. Since prior fractures and falls 
increase your risk of future fractures, we excluded beneficiaries who had any falls or fractures in the 12 
months prior to starting therapy. Finally, we required beneficiaries to remain enrolled in Medicare for at 
least 360 days following initiation to capture patterns of antihypertensive use (Figure 5).   
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Antihypertensive Adherence Trajectories 
Antihypertensive adherence trajectories in the one year following initiation of therapy were the 
primary exposure. Adherence trajectories use were defined using date of dispensing and days supply data 
(assuming constant daily dose). Starting on the index date, we counted the number of days each month a 
beneficiary was covered by any of the following antihypertensive drug classes: ACEs, ARBs, BBs, 
CCBs, or THZ. We choose these classes based on recommendations for hypertension treatment in older 
adults.2  Months were defined in 30-day intervals. If a new prescription was filled prior to the end of the 
last days’ supply, the day of the new prescription began the day after the prior prescription would have 
ended.  
After counting the number of days covered each month, binary indicator variables were used to 
specify whether an individual was covered by an antihypertensive medication for at least 24 out of 30 
days (e.g., 80% days covered). The 80% threshold is considered to have high sensitivity (92%) and 
specificity (89%) for distinguishing between adherent and non-adherent antihypertensive patients73 and is 
associated with improved cardiovascular health.40   
Non-Vertebral Fracture Outcomes 
After identifying the one-year antihypertensive adherence trajectories, we began following 
beneficiaries for non-vertebral fractures (Figure 6).  We chose to focus on non-vertebral fractures since 
incident vertebral fractures are not well captured in claims data.101  Therefore, follow-up for fractures 
began 361 days after the date of the initial antihypertensive prescription. Fractures were identified using 
validated diagnostic and procedure codes found in Medicare Parts A and B (Appendix Table 23).99  We 
excluded fractures that had a corresponding external cause-of-injury code (E-code) relating to motor 
vehicle crashes (E810-E825).   
Covariates 
Covariates were selected based on the previous literature 30,57,91,92,102 and were defined based on 
claims during the 12 months prior to initiation. Covariates included: demographics (age, gender, and 
race),  concurrent medication use and previous use of medications associated with fractures (loop 
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diuretics, antiarrhythmics, antidepressants, antiepileptics, anxiolytics, benzodiazepines, opioids, 
hypnotics, skeletal muscle relaxants, and antipsychotics), codes for chronic comorbidities associated with 
fracture risk (diabetes, chronic kidney disease, Parkinson’s disease, Alzheimer’s disease, osteoporosis, 
BMD testing,  arrhythmia, osteoarthritis, rheumatoid arthritis, stroke, myocardial infraction, hypertension, 
orthostatic hypotension, obesity, dementia, dyslipidemia, and urinary incontinence), frailty predictors, and 
prior hospital admissions. Type of antihypertensive medication initiated on the index date was defined as 
combination therapy (e.g., more than one class of antihypertensive) vs. monotherapy.  Concurrent 
medication use was defined as the number of distinct drugs prescribed in the 14 days prior to the index 
date.  As a proxy for sociodemographic status, we identified whether beneficiaries were eligible for the 
Medicare low-income subsidy (LIS) program. LIS offers medication at a reduced cost for beneficiaries 
that are eligible due to income, family size, and household resources. We used the frailty index score 
(FIS), which was developed to predict limitations in activities of daily living, as a proxy measure of 
frailty among Medicare beneficiaries.76  Additionally, we examined the prevalence of several variables 
that were found to be positively (ambulance transfer, wheelchair/walker use, home oxygen use, hospital 
bed, difficulty walking, and vertigo) and inversely (cancer screenings) associated with limitations in 
activities of daily living.76  
Analysis 
We used group based trajectory models (GBTMs) to classify beneficiaries by patterns of 
antihypertensive adherence in the first year following initiation. GBTMs were defined using logistic 
regression models. Dependent variables were monthly binary indicators of antihypertensive use, and 
months since index date were the independent variables. Time was modeled using cubic terms. In order to 
identify the best fitting model, we started with a two-group model and subsequently added up to seven 
groups. We used Bayesian Information Criterion (BIC), trajectory group size, and the average posterior 
probability of membership to identify the optimal number of groups. BIC is a statistical measure of model 
fit with lower scores signifying better overall fit. The average posterior probability of group membership 
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signifies how well beneficiaries fit within the group that they were assigned. Trajectories were defined 
using “Proc Traj”.78 
Descriptive statistics were used to compare the prevalence of baseline covariates according to 
antihypertensive adherence trajectory. Incident fracture rates and corresponding 95% confidence intervals 
(CIs) were defined as the total number of incident fracture events divided by the total person-time at risk 
for fractures. Person-years was defined as the total number of days at risk for fractures divided by 365.25. 
We used Cox proportional hazard models to estimate hazard ratios (HRs) and 95% CIs for incident 
fractures for each antihypertensive adherence trajectory versus the most adherent trajectory group. 
Starting the day after the exposure period (Day 361) we followed beneficiaries until they had a fracture or 
until the end of the follow-up (death, disenrollment from Medicare, or December 31, 2013), whichever 
came first.  
As a sensitivity analysis, we examined whether shortening the follow-up period to 6 months 
altered the results. Additionally, to assess possible bias associated with overall health, we calculated the 
rate of mortality or disenrollment from Medicare during the follow-up period according to trajectory 
groups. Finally, we examined the rate of incident fractures during the one year period used to define 
antihypertensive adherence trajectories (Day 1- Day 360). 
6.3 Results 
We identified 209,007 Medicare beneficiaries initiating antihypertensive therapy during 2008-
2011. On average beneficiaries were 75 years of age (standard deviation [std]: 6.8), 60% were women, 
and the majority were White (85%). Most beneficiaries initiated antihypertensive therapy with one 
antihypertensive medication (87%). Of those that initiated with one antihypertensive class, the most 
frequently prescribed drug classes were BBs (32%) and ACEs (30%).  
After fitting GBTMs with different groupings, we identified the five-group trajectory model as 
the best fit for our data (Figure 7, Appendix Table 26). Using the model, beneficiaries were grouped into 
the following adherence trajectories: immediate drop-off (15%, mean adherence: 0.10); gradual drop-off 
(17%, mean adherence: 0.28); partial drop-off (11%, mean adherence: 0.69); early drop-off then rebound 
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to almost full adherence (14%, mean adherence: 0.58); and adherent (43% of the population, mean 
adherence: 0.97) (Table 11).   
When comparing the prevalence of baseline covariates across trajectory groups, the prevalence of 
the following baseline covariates differed across trajectory groups: gender, race, initiation with 
combination therapy, opioid use, diabetes, cardiovascular disease (e.g., arrhythmia, hypertension, and 
dyslipidemia), vertigo, cancer screenings, and prior hospitalizations (Table 12).   
During the one year follow-up period, beneficiaries had a total of 8,678 non-vertebral fracture 
events over 209,007 person-years of follow-up (rate= 442 fractures per 10,000 person-years, 95% CI: 
433-452). Most of the fractures resulted in single bone breaks (76%, n=6,682), and fractures most 
commonly occurred at the hip (23%), foot (16%), radius (16%), and hand (13%). 
When examining fracture rates during the second year after initiation of therapy according to 
antihypertensive adherence trajectory, beneficiaries belonging to the adherent trajectory had the lowest 
rate of fractures (416 fractures per 10,000 person-years, 95% CI: 402-430), and beneficiaries belonging to 
the partial drop-off trajectory had the highest fracture rate (491 per 10,000 person-years, 95% CI:462-
522). After adjusting for baseline covariates, beneficiaries belonging to the partial drop-off trajectory had 
the highest rate of fractures compared to beneficiaries who were adherent (Adjusted HR: 1.20, 95% CI: 
1.12-1.29).  The results were similar when we limited the fracture follow-up time to six months (Table 
13). 
In the sensitivity analysis, the one year mortality or disenrollment rate was lowest among 
beneficiaries belonging to the adherent trajectory group (702 per 10,000 person-years, 95% CI: 684-719). 
Rates of death or disenrollment were highest among beneficiaries belonging to the immediate drop-off 
trajectory group (925 per 10,000 person-years, 95% CI: 891, 960). The elevated rate of mortality or 
disenrollment in the immediate drop-off trajectory group remained after controlling for baseline 
covariates (adjusted HR: 1.32, 95% CI: 1.26, 1.38) (Appendix Table 27). Additionally, the results were 
similar when we examined the rates of incident fracture during the initial 360 days following initiation of 
therapy (Table 14).  
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6.4 Discussion 
Among Medicare beneficiaries initiating antihypertensive therapy, we found that antihypertensive 
adherence trajectories differ in the year following initiation. We identified five adherence trajectories 
ranging from beneficiaries who were fully adherent to beneficiaries who never returned after the initial 
prescription.  Medicare beneficiaries who were more adherent to their antihypertensive medication had 
lower fracture rates during the follow-up period.  
In the year following initiation, we identified five different antihypertensive adherence 
trajectories. This number of adherence trajectories is lower than our previous study which identified six 
antihypertensive adherence trajectories.107  However, the six group trajectory model failed to converge in 
the current study and resulted in small group sizes. The smaller number of trajectory groups identified is 
most likely due to the smaller sample size included in this study.  In the current study we included 
additional exclusion criteria that reduced the sample size by nearly 80,000 beneficiaries compared to our 
first study. Results suggest that GBTMs are largely dependent on sample size.  Future studies using 
GBTMs to quantify medication adherence need to be aware of the potential impact group size has the 
results.  
Overall, we found that the rates of non-vertebral fractures were lowest among older adults who 
were adherent to their antihypertensive therapy.  This result may be due to a protective effect from 
antihypertensives or it could be due to residual confounding related to the healthy user bias. In our 
sensitivity analysis, we found that older adults in the adherent group also had the lowest rate of mortality 
or disenrollment compared to older adults in other trajectory groups. Older adults who are in better health 
may be at lower risk of both falling and sustaining injuries from falls due to increased exercise or 
improved bone health. More research is needed featuring clinical BMD measurements or physical activity 
measures to better control for confounding caused by the healthy user bias.  
Medicare beneficiaries belonging to the partial drop-off adherence trajectory had the highest rate 
of fractures compared to beneficiaries in other trajectory groups. This result may be due to changes in 
overall health during the exposure period. Although we tried to control for various risk factors for 
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fractures prior to antihypertensive initiation, our GBTM results are not adjusted for time-varying 
confounders. Older adults experiencing adverse medication events or cardiovascular events during the 
exposure period may be at higher risk of having a subsequent fall or fracture during the follow-up period. 
Future research studies using adherence trajectories as exposures for future events should include time-
varying covariates in the model to allow for changing health status over the exposure period. 
 This was the first study to use GBTMs to examine the association between antihypertensive 
adherence and subsequent fractures among older adults initiating therapy. Given the substantial impact 
fractures can have on older adults, it is important to identify ways to reduce the risk of fractures among 
this population. Our results suggest that better antihypertensive adherence may be associated with fewer 
fractures among older adults. However, our results were not adjusted for changes in overall health during 
the exposure period and subject to residual confounding. More research is needed taking into account 
changes in overall health to further examine the association between antihypertensive adherence and 
fractures.   
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Table 11: Antihypertensive adherence trajectories in the 12 months following initiation 
according to adherence measures (n=209,007) 
Adherence  Trajectory 
Group Size 
Average 
Probability of 
Adherencea 
Average Posterior 
Probabilityb 
N % Mean Std Mean Std 
Immediate Drop-off 31,482 15.1 0.10 0.25 0.95 0.07 
Gradual Drop-off 36,231 17.3 0.28 0.31 0.85 0.17 
Partial Drop-off 22,510 10.8 0.69 0.26 0.84 0.16 
Early Drop-off then Rebound 29,197 14.0 0.58 0.20 0.87 0.16 
Adherent  89,587 42.9 0.97 0.02 0.96 0.10 
a Average probability of being at least 80% adherent over 12 months of follow-up. 
b Indicates how well beneficiaries fit in their assigned group. 0.70 is typically used as a 
threshold to signify good model fit. 
Std= standard deviation. 
BIC= Bayesian information criterion. BIC is used as a measure of model fit. Lower BIC 
values signify better model fit. 
Logistic regression models were used to identify trajectory groups. The dependent variables 
were the monthly binary indicators of antihypertensive use and months since start of 
antihypertensive therapy were the independent variables. Time was modeled using cubic 
terms. 
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Table 12: Characteristics of Medicare beneficiaries initiating antihypertensive therapy between 
2008-2011 according to one year adherence trajectory (n=209,007) 
 
Immediate 
Dropoff 
n=31,482 
Gradual 
Dropoff 
n=36,231 
Partial 
Dropoff 
n=22,510 
Early Dropoff 
then Rebound 
n=29,197 
Adherent 
n=89,587 
Mean Age, std (years) 75.1 (6.9) 74.9 (6.8) 74.7 (6.8) 74.9 (6.9) 74.6 (6.8) 
Mean Frailty Index, std 0.09 (0.1) 0.08 (0.1) 0.08 (0.1) 0.08 (0.1) 0.08 (0.1) 
Male, % 39.0 41.5 41.1 38.9 38.9 
White  Race, % 81.1 80.4 84.8 81.5 88.9 
Low-Income Subsidy, %  5.2 5.3 5.0 5.2 5.1 
Medication History, %      
1-2 Meds Filleda 59.5 60.6 60.5 61.1 59.3 
3-4 Meds Filleda 29.1 28.1 27.6 27.9 28.1 
5 + Meds Filleda 11.4 11.3 11.9 11.0 12.6 
Combo Initiationb 8.1 11.5 13.4 12.1 16.4 
Loop Diuretic  5.2 5.3 5.4 5.5 5.7 
Antiarrhythmic 4.2 3.7 3.5 3.5 3.3 
Antidepressantc 15.0 14.6 15.0 14.8 14.2 
Antipilepticc 7.9 7.8 7.3 7.5 6.9 
Anxiolytic 4.5 3.9 3.6 3.6 3.3 
Benzodiazpenec 1.5 1.2 1.2 1.2 1.2 
Bisphosphonate 10.7 10.4 10.8 10.7 11.3 
Antipsychoticsc 3.2 2.7 2.8 2.8 3.0 
Skeletal Muscle 
Relaxantc 7.3 6.9 6.1 6.9 5.7 
Opioid 32.1 28.9 28.0 29.4 25.8 
Hypnoticc 7.7 7.1 6.8 7.2 6.2 
Chronic Conditions, %      
Diabetes 22.3 25.1 24.8 26.0 23.1 
Chronic Kidney 
Disease 9.5 9.1 9.3 9.8 9.0 
Parkinson's Disease 1.4 1.2 1.3 1.1 1.0 
Alzheimer's Disease 2.4 2.3 2.6 2.3 2.6 
Osteoporosis 16.1 15.4 15.4 15.5 15.1 
Arrhythmia 17.1 16.5 17.3 15.6 18.8 
Osteoarthritis 17.1 16.1 15.6 16.3 14.8 
Rheumatoid Arthritis 3.2 3.1 2.8 3.0 2.6 
Stroke 13.4 13.1 13.7 13.4 14.1 
Myocardial Infarction 1.0 1.3 1.8 1.2 2.7 
Hypertension 63.7 71.7 77.5 76.9 79.5 
Orthostatic 
Hypertension 0.9 0.8 0.8 0.7 0.6 
Syncope 5.1 4.8 4.7 4.5 4.8 
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Dementia 4.7 4.4 5.1 4.7 5.0 
Urinary Incontinence 5.1 4.6 4.8 4.5 4.4 
Dyslipidemia 59.7 62.8 65.1 64.4 64.8 
Obesity 3.7 4.0 4.2 4.1 4.2 
Frailty Indicators, %      
Home Oxygen Use 3.3 2.8 2.4 2.5 2.3 
Walker Use  1.9 1.7 1.6 1.8 1.6 
Wheelchair Use 0.9 0.8 0.8 0.9 0.7 
Hospital Bed 0.5 0.4 0.5 0.4 0.4 
Difficulty Walking 8.2 7.6 7.6 7.8 7.5 
Vertigo 14.7 13.5 12.6 13.1 11.8 
Ambulance Transport 8.9 7.7 7.9 7.5 8.6 
Cancer Screenings 36.7 37.0 39.9 38.7 41.9 
Hospital Utilization, %      
Hospital Admissions 18.8 15.7 16.0 15.1 17.3 
a Number of distinct medications filled 14 days prior to the index date (initiation of therapy)  
b Combination therapy was defined as having more than one class of antihypertensive prescribed on 
the index date. Includes both single pill combination therapy and multiple pill combination 
therapy.   
c Medication indicated to be associated with elevated risk of fractures according to the 2015 Beers 
Medication Guideline released by the American Geriatrics Society 
Race was missing for a total of 246 beneficiaries and these were excluded from the analysis 
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Table 13: Rates and adjusted hazard ratios (HRs) of fractures in the second year of initiating antihypertensive therapy according to one year 
antihypertensive adherence trajectories 
1-182 Day Period  365 Day Period  
Drug Class 
# 
Fractures P-Yrs 
Rate Per 
10,000 p-yrs 
(95% CI) 
  Adjusted HR 
 (95% CI) 
# 
Fractures P-Yrs 
Rate Per 
10,000 p-yrs 
(95% CI) 
   Adjusted HR  
(95% CI) 
Immediate Drop-off 784 15,102 519 (484-556) 1.13 (1.04, 1.22) 1,374 29,320 469 (444-494) 1.11 (1.04, 1.18) 
Gradual Drop-off 843 17,425 484 (452-517) 1.09 (1.01, 1.18) 1,454 33,881 429 (408-452) 1.06 (1.00, 1.13) 
Partial Drop-off 614 10,801 569 (525-614) 1.27 (1.16, 1.39) 1,031 20,999 491 (462-522) 1.20 (1.12, 1.29) 
Early Drop-off then 
Rebound 759 14,042 541 (503-580) 1.20 (1.10, 1.30) 1,297 27,286 475 (450-502) 1.15 (1.08, 1.23) 
Adherent  1,986 43,339 458 (438-479) ref 3,552 84,662 416 (402-430) ref 
HR’s are adjusted for all baseline covariates, CI= Confidence Interval 
P-Yrs= person-years of follow 
Follow-up for fractures began after the one year exposure period used to define the trajectory groups (e.g., started on day 361 after initiation 
of antihypertensive therapy). 
 59 
Table 14: Sensitivity analysis examining the rates of incident fracture in the first year following 
initiation of antihypertensive therapy according to antihypertensive adherence trajectories 
Drug Class 
# 
Fractures P-Yrs 
Rate Per 10,000 p-
yrs (95% CI) 
  Adjusted HR 
 (95% CI) 
Immediate Drop-off 1,174 30,450 386 (364-408) 1.23 (1.14, 1.31) 
Gradual Drop-off 1,289 35,078 368 (348-388) 1.22 (1.14, 1.30) 
Partial Drop-off 928 21,760 427 (400-455) 1.40 (1.30, 1.51) 
Early Drop-off then Rebound 1,131 28,176 401 (379-425) 1.31 (1.23, 1.41) 
Adherent  2,694 87,000 310 (298-322) ref 
HR’s are adjusted for all baseline covariates 
P-Yrs= person-years of follow 
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Figure 5: Flowchart of eligibility criteria for identifying Medicare beneficiaries initiating antihypertensive 
therapy between 2008 and 2011. 
 
 Medicare beneficiaries                
(≥ 66 YOA) initiating 
antihypertensive therapy between 
2008 and 2011 
N= 373,894 
Included in Study 
N= 209,007 
Excluded (n=147,560): 
 Originally eligible for Medicare due to 
disability or end stage renal disease 
(n=37,798, 25.6%) 
 Not enrolled for at least 360 days after the 
index date (n=38,540, 26.1%) 
 Prior nursing home stays (n=21,309, 14.4% ) 
 Prior diagnosis of acute tremor disorder or 
congestive heart failure (n= 28,967, 19.6%) 
 Prior fractures or falls (n= 17,984, 12.2%) 
 Metastatic Cancer (n=2,962, 2.0%) 
 
First qualification of new use 
N= 356,567 
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Figure 6: Study design used to assess antihypertensive adherence trajectories and fractures 
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Figure 7: Antihypertensive adherence trajectories among Medicare beneficiaries initiating 
antihypertensive therapy between 2008 and 2011 
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CHAPTER 7: FALLS VS FRACTURES: THE IMPACT OUTCOME DEFINITION HAS ON 
THE ASSOCIATION BETWEEN ANTIHYPERTENSIVES MEDICATION AND ADVERSE 
EVENTS  
7.1 Introduction 
Falls are the leading cause of fatal and non-fatal injury among older adults, and an estimated one 
out of three older adults fall each year.50  Fractures are one of the most common fall-related injuries.89  In 
older adults, falls and fractures are associated with high medical costs, loss of independence, and an 
increased risk of mortality.43,44,90  Older adults are at a greater risk of falls due to impaired balance or gait,  
increased presence of comorbidities, and increased medication use.30,91,113   
Recently, evidence suggests that antihypertensive medications can increase the risk of falls and 
fractures among older adults.11,63,114  Antihypertensive medications can increase the risk of falls by 
causing orthostatic hypotension.  Orthostatic hypotension is defined as a drop in blood pressure upon 
standing and is a risk factor for falls among older adults.68  Orthostatic hypotension is a possible adverse-
medication related event reported with thiazide diuretics (THZs) and beta blockers (BBs).2,30  
Antihypertensives can also impact the risk of whether a fracture occurs as a result of a fall through 
interactions with BMD.  For instance, thiazide diuretics have been found to stimulate the formation of 
osteoblasts potentially providing a protective effect for fractures.32  Angiotensin-receptor blockers 
(ARBs) and angiotensin-converting-enzyme inhibitors (ACEs) are believed to impact BMD by inhibiting 
bone turnover caused by the renin-angiotensin-aldosterone system (RAAS),32 and have been found to be 
associated with a lower risk of falls and fractures. 67,115     
Despite falls being the primary cause of fractures among older adults, no prior study has 
examined the impact of outcome definition (falls vs. fractures) has on the association between 
antihypertensives and these adverse events. Prior research has found that THZs are associated with a 
lower risk of both falls and fractures in the first few weeks following initiation.10,11  However, previous 
 64 
research examining the association between antihypertensives and adverse events is less consistent after 
longer periods of use.11  
In this study we sought to examine the association between antihypertensives and incident falls 
according to antihypertensive class and time since initiation. As a secondary analysis, we examined how 
using fractures as the outcome altered the results.   
7.2 Methods 
We used a 20% nationwide, random sample of fee-for-service Medicare beneficiaries with at least 
one month of combined parts A (inpatient care), B (outpatient care), and D (prescription drugs) coverage 
between 2007 and 2011. Data were obtained under a data use agreement established with the Centers for 
Medicaid and Medicare Services (CMS) and the University of North Carolina (UNC) at Chapel Hill. The 
study protocol was approved by the UNC Institutional Review Board.  
Study Population 
The study cohort consisted of Medicare beneficiaries initiating therapy with antihypertensive 
medications during 2008-2011 who were enrolled in Medicare Parts A, B, and D for at least 12 months 
prior to initiation. New use was defined as not having a prior prescription for any of the following 
antihypertensive medications in the last 12 months: angiotensin-converting-enzyme inhibitors (ACE), 
angiotensin-receptor blockers (ARB), beta blockers (BB), calcium channel blockers (CCB), or thiazide 
diuretics (THZ). The eligibility and exclusion criteria for the study population has previously been 
described (see Chapter 5, Appendix Figure 11). 
Exposure 
The primary exposure was initiation of antihypertensive therapy with one of the following drug 
classes: ACEs, ARBs, BBs, CCB, or THZ.   These specific drug classes were chosen based on the current 
recommendations for hypertension treatment in older adults.2,13  Loop diuretics were not included as a 
primary exposure since these medications are typically given to older adults with a higher number of 
comorbidities and at greater risk of mortality.27  Prescription medication data were identified using 
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Medicare Part D (Appendix Table 18). Using fill dates, we identified the date of the initial prescription 
for antihypertensive therapy.  
Outcome 
Incident falls within 12 months of initiating antihypertensive monotherapy were our primary 
outcome. Starting the day after the initial antihypertensive prescription, we followed beneficiaries until 
the first fall event. Falls were identified using external-cause-of-injury (E-codes) in Medicare Parts A and 
B (E880-E888).  
As a secondary outcome, we identified incident non-vertebral fractures.  Fractures were identified 
using validated diagnostic and procedure codes found in Medicare Parts A and B.99  Only fractures that 
had both a fracture diagnosis and a corresponding procedure code within seven days of the fracture 
diagnosis were included (Appendix Table 23).  We excluded fractures that were due to motor vehicle 
crashes (E810-E825) and those that occurred on the index date.  
Covariates 
Covariates were selected based on previous literature 30,57,91,92,102 and were identified using claims 
in the 12 months prior to initiation (Appendix Table 24). Covariates included: demographics, concurrent 
medication use (e.g., number of distinct drugs prescribed in the 14 days prior to the index date) and use of 
medications associated with falls and fractures (loop diuretics, antiarrhythmics, antidepressants, 
antiepileptics, anxiolytics, benzodiazepines, opioids, hypnotics, skeletal muscle relaxants, and 
antipsychotics), chronic comorbidities associated with fall  risk (diabetes, chronic kidney disease, 
Parkinson’s disease, Alzheimer’s disease, osteoporosis, BMD testing,  arrhythmia, osteoarthritis, 
rheumatoid arthritis, stroke, myocardial infraction, hypertension, orthostatic hypotension, obesity, 
dementia, dyslipidemia, and urinary incontinence), frailty predictors, and previous hospital admissions. 
As a proxy for sociodemographic status, we identified whether beneficiaries were eligible for the 
Medicare low-income subsidy (LIS) program. LIS offers medication at a reduced cost for beneficiaries 
that are eligible due to income, family size, and household resources.  We used the frailty index score 
(FIS) as a proxy measure of frailty among Medicare beneficiaries.76  Additionally, we examined the 
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prevalence of several variables that were found to be positively (ambulance transfer, wheelchair/walker 
use, home oxygen use, hospital bed, difficulty walking, and vertigo) and inversely (cancer screenings) 
associated with limitations in activities of daily living.76  
Analysis 
Descriptive statistics were used to compare the prevalence of baseline covariates according to 
antihypertensive class initiated on the index date. We estimated propensity scores using multinomial 
logistic regression models to adjust for differences in the distribution of baseline covariates.  Standardized 
mortality ratio (SMR) weighting was used to weight beneficiaries of each drug class to achieve the same 
baseline covariate distribution as the one observed in beneficiaries receiving an ACE.105  ACEs were used 
as the referent since they were the most commonly prescribed drug class.106  To assess the effectiveness 
of the SMR weights, we examined the distribution of baseline covariates after SMR weighting and 
examined the distribution of the SMR weights according to drug class.  After identifying outlier SMR 
weights, we removed the 0.1% tail ends.    
Incident fall rates and corresponding 95% confidence intervals (CIs) were defined as the total 
number of falls divided by the total person-time at risk. Person-time at risk was defined as the total days 
at risk divided by 365.25. We used SMR-weighted Cox proportional hazard models to estimate hazard 
ratios (HRs) and 95% CIs of incident falls for each drug class initiated on the index date versus receiving 
an ACE according to days since initiation of therapy, 1-14 days and 15-365 days. CIs were calculated 
using robust standard errors to account for SMR weights. We used an ‘first-treatment-carried-forward’ 
analysis to avoid introducing confounding by indication since antihypertensive adherence patterns vary 
over time and beneficiaries who remain adherent may differ from the majority of hypertensive patients.107 
Beneficiaries contributed person-time at risk until they had an incident event or until the end of the 
follow-up (death, disenrollment from Medicare, or December 31, 2012), whichever came first. To 
examine the impact outcome definition has on the results, we repeated the primary analysis using incident 
fractures as the outcome. 
 67 
As a sensitivity analysis, we repeated the primary analysis removing beneficiaries with chronic 
kidney disease or diabetes since these chronic conditions could impact a physicians’ choice in which 
antihypertensive class is prescribed.  
7.3 Results 
Between 2008 and 2011, 122,629 Medicare beneficiaries initiated monotherapy with 
antihypertensive medications. Beneficiaries were on average 75 years of age, 61% were women, and 86% 
were White. The most common classes of antihypertensives prescribed were ACEs (33%), BBs (30%), 
and CCBs (15%).  Before SMR weighting, demographics, diabetes, chronic kidney disease, 
cardiovascular disease (e.g., arrhythmia, stroke, hypertension, and dyslipidemia), ambulance transfers, 
cancer screenings, and prior hospitalizations differed across beneficiaries according to antihypertensive 
class.  After SMR weighting, there was little difference between baseline characteristics according to 
antihypertensive class (Table 8).  
During the first year after initiating antihypertensive monotherapy, beneficiaries experienced 
6,893 incident falls over a period of 114,843 person-years (rate = 600 per 10,000 person-years, 95% CI: 
586-615). Twenty-eight percent of falls resulted in fractures (n=1,981). Fractures most commonly 
occurred at the hip (29%), radius (18%), humerus (13%), and rib (10%).  
Rates of incident falls varied according to antihypertensive class (Table 15). Beneficiaries who 
initiated with CCBs had the highest rate of falls in the first 14 days (709 per 10,000 person-years, 95% 
CI: 532-928) and during the 15-365 days after initiation (701 per 10,000 person-years, 95% CI: 661-742). 
Beneficiaries who initiated with ACEs had the lowest rate of falls during the initial 1-14 days (526 per 
10,000 person-years, 95% CI: 421-651). However, beneficiaries who initiated with ARBs had the lowest 
rate of falls during the 15-365 days after initiation (534 per 10,000 person-years, 95% CI: 490-581).  
After controlling for differences in baseline characteristics, beneficiaries who initiated with BBs had the 
highest rate of falls in the first 14 days compared to beneficiaries who initiated with ACEs (SMR HR: 
1.13, 95% CI: 0.75-1.70).  After the first 14 days, beneficiaries who initiated with THZs had the lowest 
rate of falls compared to beneficiaries who initiated with ACEs (SMR HR: 0.96, 95% CI: 0.87-1.07).  
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When we repeated the analysis using fractures as the outcome, the association between 
antihypertensive class and incident fractures varied according to time since initiation of therapy (Table 
15). During the first 14 days, beneficiaries who initiated with THZs (438 per 10,000 person-years, 95% 
CI: 294-628) and BBs (410 per 10,000 person-years, 95% CI: 314-526) had the highest fracture rates. 
However, beneficiaries who initiated therapy with CCBs had the highest fracture rate during the 15-365 
days after initiation (435 per 10,000 person-years, 95% CI: 404-468). Beneficiaries who initiated with 
ARBs had the lowest fracture rate during the initial 1-14 days (333 per 100 person-years, 95% CI: 190-
546) and during the 15-365 days after initiation (321 per 100 person-years, 95% CI: 287-358).  
After controlling for differences in baseline characteristics, beneficiaries who initiated with THZs 
had the highest fracture rate in the first 14 days compared to beneficiaries who initiated with ACEs (SMR 
HR: 1.42, 95% CI: 0.79-2.57). After the first 14 days, beneficiaries who initiated with CCBs (SMR HR: 
1.09, 95% CI: 0.97-1.22) and BBs (SMR HR: 1.04, 95% CI: 0.93-1.15) had slightly higher fracture rates 
compared to the beneficiaries who initiated with ACEs.  
In the sensitivity analysis when we removed beneficiaries with chronic kidney disease or 
diabetes, beneficiaries who initiated with ARBs had the lowest rate of falls and fractures in the first two 
weeks and during the 15-365 days after initiation compared to beneficiaries who initiated with ACEs 
(Table 16).  
7.4 Discussion 
Among Medicare beneficiaries initiating antihypertensive monotherapy, the association between 
antihypertensives and adverse events in the year following initiation differed according to 
antihypertensive class and by outcome definition (falls vs. fractures).  When using falls as the primary 
outcome, initiating with CCBs was associated with an elevated rate of falls in the year after initiation. 
However, when using incident fractures as the primary outcome, results varied according to time since 
initiation. In the first two weeks, beneficiaries who initiated therapy with THZs had the highest rate of 
fractures. After the first two weeks, initiating with CCBs was associated with the highest rate of fractures. 
Initiating with ARBs was associated with the lowest rates of both falls and fractures.  
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Overall, Medicare beneficiaries initiating with ARBs had the lowest rate of both falls and 
fractures in the 15-365 days following initiation.  ARBs lower blood pressure by regulating of the renin-
angiotensin-aldosterone system (RAAS), and have been suggested to provide protective effects for 
fractures by preventing bone loss induced by RAAS.32,67,115   This potential protective effect of BMD may 
explain the lower rate of fractures we found in our study, but the time it takes to achieve clinically 
relevant BMD effects is not known. Our results suggest that more research is needed to examine the 
potentially protective effect ARBs have on preventing fractures by inhibiting bone turnover caused by the 
renin-angiotensin-aldosterone system.32  The lower rate of falls we observed among ARB users may be 
due to a lower risk of adverse medication events, such as orthostatic hypotension or urinary incontinence. 
Compared to other classes of antihypertensives, ARBs are associated with fewer side effects and have 
higher levels of adherence.33,34  If given the choice between antihypertensive classes, clinicians may want 
to consider prescribing ARBs to older adults as first line treatment for hypertension.  
Despite the similar results for beneficiaries initiating with ARBs, overall we found that the 
association between antihypertensives and adverse events differed depending on the outcome. One of the 
main reasons for the differences in results may be related to the accuracy of reporting falls and fractures 
in claims data. Falls are captured in claims data using E-codes, however E-code reporting is not required 
by every state.100  Additionally, few studies have reported the accuracy of E-code reporting in clinical 
data.116 Fractures, on the other hand, are identified using validated diagnostic and procedure codes in 
claims data. The sensitivity and specificity of fracture codes vary by fracture type, ranging from 97% 
sensitivity for hip fractures to 25% for thorax fractures.99,117 Additionally, unlike E-codes, hospitals are 
incentivized to report fractures diagnostic and procedure codes for reimbursement purposes.100  Results 
suggests that when examining the association between adverse events and antihypertensives, researchers 
should keep in mind the impact outcome definition can have on the results.  
Despite this being the first study to examine the impact of outcome definition has on the 
association between antihypertensives and adverse events, this study does have limitations. First, our 
results may be subject to residual confounding. We used SMR weights to limit confounding by indication 
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but were unable to control for physical activity, baseline BMI levels, visual impairment, and alcohol use. 
Second, our study population was predominantly White Medicare beneficiaries. It is unknown if these 
results would hold true for non-White older populations. Third, our results are limited to the one year 
period following initiation. One year may not have been long enough to identify all the possible BMD 
effects. Lastly, results did not take into account antihypertensive dose. Previous research has found that 
the relationship between antihypertensives and fractures is linearly associated with increasing dose.11,64  
Results from our study may be underestimated for older adults on higher doses of antihypertensive drugs. 
Overall, we found that ARBs were associated with fewer adverse events compared to the other 
antihypertensive drug classes. However, for other classes of antihypertensive drugs, the association 
between antihypertensives and subsequent injury differs depending on whether falls or fractures is used as 
the outcome. These results suggest that it is important to keep in mind the impact outcome definition can 
have on the results.  Additionally, our results suggest that clinicians may want to consider different risks 
of adverse events when choosing between antihypertensive drug classes. 
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Table 15: Rates of incident falls and fractures in the first year after initiation among Medicare beneficiaries starting 
antihypertensive monotherapy between 2008-2011 (n=122,629) 
1-14 Days After Initiation  15-365 Days After Initiation 
Drug 
Class 
# Falls P-Yrs 
Rate Per 10,000 
P-yrs (95% CI) 
SMRW Adj HR 
 (95% CI) 
# Falls P-Yrs 
Rate Per 10,000  
P-Yrs (95% CI) 
SMRW Adj HR 
(95% CI) 
ACE 81 1,539 526 (421, 651) ref 1,986 36,253 548 (524, 572) ref 
ARB 25 419 597 (395, 868) 1.12 (0.67, 1.85) 530 9,932 534 (490, 581) 0.99 (0.89, 1.09) 
BB 94 1,415 664 (540, 809) 1.13 (0.75, 1.70) 2,144 33,088 648 (621, 676) 0.99 (0.91, 1.08) 
CCB 50 705 709 (532, 928) 1.04 (0.67, 1.62) 1,144 16,328 701 (661, 742) 1.05 (0.96, 1.15) 
THZ 34 617 551 (388, 761) 1.06 (0.65, 1.71) 805 14,547 553 (516, 593) 0.96 (0.87, 1.07) 
Results when using incident fractures as the outcome 
Drug 
Class 
# 
Fractures P-Yrs 
Rate Per 10,000  
P-Yrs (95% CI)  
SMRW Adj HR  
(95% CI) 
# 
Fractures P-Yrs 
Rate Per 10,000  
P-Yrs (95% CI) 
SMRW Adj HR 
(95% CI) 
ACE 54 1,539 351 (266, 454) ref 1,271 36,618 347 (328, 367) ref 
ARB 14 420 333 (190, 546) 0.91 (0.48, 1.74) 322 10,032 321 (287, 358) 0.96 (0.85, 1.09) 
BB 58 1,416 410 (314, 526) 0.95 (0.57, 1.58) 1,375 33,449 411 (390, 433) 1.04 (0.93, 1.15) 
CCB 27 705 383 (258, 550) 0.79 (0.46, 1.35) 720 16,540 435 (404, 468) 1.09 (0.97, 1.22) 
THZ 27 617 438 (294, 628) 1.42 (0.79, 2.57) 562 14,656 384 (353, 416) 1.00 (0.89, 1.13) 
We removed 0.1% of the outlier SMR weights when calculating the adjusted SMR HRs. Adjusted 95% confidence intervals 
were calculated using robust standard errors.  
P-Yrs= person-years of follow (calculated by dividing the total number of follow-up days by 365.25) 
SMRW= Standardized mortality ratio weighted 
CI= confidence interval 
HRs and 95% CIs are adjusted for SMRWs that were calculated using all the baseline covariates 
Angiotensin converting enzyme inhibitors (ACE), angiotensin receptor blockers (ARB), beta blockers (BB), calcium channel 
blockers (CCB), or thiazide diuretics (THZ) 
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Table 16: Rates of incident falls and fractures in the first year after initiation among Medicare beneficiaries without chronic 
kidney disease or diabetes starting antihypertensive monotherapy between 2008-2011 (n=86,420) 
1-14 Days After Initiation 15-365 Days After Initiation 
Drug 
Class 
# Falls P-Yrs 
Rate Per 10,000 
P-Yrs (95% CI) 
SMRW Adj HR 
(95% CI) 
# Falls P-Yrs 
Rate Per 10,000 
P-Yrs (95% CI) 
SMRW Adj HR 
(95% CI) 
ACE 52 979 531 (401-691) ref 1,213 23,156 524 (495-554) ref 
ARB 12 267 449 (244-761) 0.84 (0.41, 1.73) 324 6,340 511 (458-569) 0.98 (0.86, 1.11) 
BB 62 1,045 593 (459-756) 1.08 (0.66, 1.78) 1,506 24,560 613 (583-645) 0.99 (0.89, 1.10) 
CCB 37 513 721(515-984) 1.01 (0.62, 1.64) 767 11,984 640 (596-687) 0.98 (0.88, 1.09) 
THZ 28 505 554 (376-791) 1.11 (0.68, 1.81) 638 11,952 534 (494-577) 0.94 (0.85, 1.05) 
Results when using incident fractures as the outcome 
Drug 
Class 
# 
Fractures P-Yrs 
Rate Per 10,000 
P-Yrs (95% CI) 
SMRW Adj HR 
(95% CI) 
# 
Fractures P-Yrs 
Rate Per 10,000  
P-Yrs (95% CI)  
SMRW Adj HR 
(95% CI) 
ACE 32 979 327 (227-456) ref 774 23,373 331 (308-355) ref 
ARB <11 NR 300 (139-569) 0.94 (0.39, 2.25) 196 6,398 306 (266-352) 0.97 (0.82, 1.14) 
BB 45 1,045 431 (318-571) 1.41 (0.79, 2.52) 994 24,799 401 (377-426) 1.01 (0.89, 1.15) 
CCB 19 513 370 (230-568) 0.95 (0.49, 1.84) 517 12,116 427 (391-465) 1.08 (0.95, 1.23) 
THZ 22 505 436 (280-649) 1.29 (0.72, 2.32) 456 12,031 379 (345-415) 1.02 (0.90, 1.16) 
We removed 0.1% of the outlier SMR weights when calculating the adjusted SMR HRs (n=65,358). 95% confidence 
intervals were calculated using robust standard errors.  
P-Yrs= person-years of follow (calculated by dividing the total number of follow-up days by 365.25) 
SMRW= Standardized mortality ratio weighted, CI= confidence interval 
HRs and 95% CIs are adjusted for SMRWs that were calculated using all the baseline covariates 
Angiotensin converting enzyme inhibitors (ACE), angiotensin receptor blockers (ARB), beta blockers (BB), calcium 
channel blockers (CCB), or thiazide diuretics (THZ) 
NR= non-reportable 
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CHAPTER 8: DISCUSSION 
8.1 Overall Summary of Findings 
The primary objectives of our first aim were to 1) use GBTMs to identify antihypertensive 
adherence trajectories in the first year following initiation; 2) compare adherence trajectories to traditional 
adherence measures; and 3) examine whether patient characteristics can predict adherence trajectories. 
We found that antihypertensive adherence patterns vary among older adults initiating therapy. Using 
GBTMs, we identified six different antihypertensive adherence trajectories ranging from older adults that 
were always adherent to those who stopped therapy after the first prescription. Nearly half of older adults 
initiating antihypertensive therapy remained adherent in the year following initiation. Compared to 
traditional adherence measures, GBTMs were better at distinguishing between adherent and non-adherent 
older adults. We found that certain patient characteristics were predictive of belonging to a less adherent 
trajectory group. Individual characteristics predictive of non-adherence include: non-White race, initiation 
with one class of antihypertensive drug, no history of cardiovascular disease, higher probability of being 
frail, Parkinson’s disease, opioid use, and no history of being in the Medicare insurance gap period. Poor 
persistence to other chronic medication was also predictive of being non-adherent.   
 The primary objectives of our second aim were to 1) estimate the rate of fractures according to 
antihypertensive adherence trajectories; 2) estimate the rate of fractures according to duration of use; 3) 
examine the association between antihypertensives and type of fracture outcomes; and 4) examine the 
impact of using falls versus fractures as the primary outcome between antihypertensive and adverse 
events. Overall, we found that the rate of incident fractures in the year following initiation of 
antihypertensive therapy differs by antihypertensive class. During the first two weeks following initiation 
of therapy, older adults who initiated with THZs or BBs had an initial elevated rate of fractures compared 
to older adults who initiated with other classes of antihypertensive drugs.  Older adults who initiated with 
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ARBs had the lowest rates of both falls and fractures in the one year following initiation. Better 
antihypertensive adherence in the year following initiation was associated with fewer fractures.  Lastly, 
although fractures are often the result of a fall, we found that the association between most 
antihypertensive classes and adverse events differs depending on whether falls or fractures are used as the 
outcome.   
8.2 Public Health Implications 
Antihypertensive medications can reduce the risk of cardiovascular disease among hypertensive 
patients. We found that nearly half of older adults were adherent to their antihypertensive medication in 
the year following initiation. However, a large proportion of older adults with cardiovascular disease were 
not adherent. We found that initiation with monotherapy, no prior history of cardiovascular disease, and a 
low probability of being frail are strong predictors of non-adherence.  Since hypertension is an 
asymptomatic disease, older adults who perceive they are in overall good health (e.g., those with no prior 
cardiovascular disease, or those with mild cases of hypertension) may be less likely to remain adherent 
compared to older adults who perceive their health to be poor.2  Our results suggest that older adults 
should be made aware of the importance of being adherent. Specifically, older adults need to be aware of 
the potential health consequences of being non-adherent to their antihypertensive medications. Previous 
research has found that a better understanding of the value of taking antihypertensives by both patients 
and/or caregivers, is associated with improved adherence among hypertensive patients.118   Results from 
this study can be used to identify sub-populations of older adults at greater risk of being non-adherent to 
their antihypertensive medication. Future research studies may want to consider targeting 
antihypertensive adherence interventions, such as setting reminders to encourage older adults to take their 
medication,119,120 for these sub-populations at greater risk of non-adherence.  
Given that hypertension is asymptomatic, some instances of non-adherence are likely to due to 
medication adverse-events. Fractures are an example of one unwanted side effect caused by initiation 
with antihypertensive medications. In older adults, fractures are associated with high medical costs, loss 
of independence, and an increased risk of mortality.43,44,90  In Aim 2, we found that certain sub-classes of 
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antihypertensive medication are associated with elevated rates of fractures and falls among older adults. 
As the older adult population increases, it is important that researchers and clinicians identify modifiable 
factors that can reduce the risk of fractures and falls among this population. Our results suggest that the 
choice of antihypertensive medication prescribed may be one way clinicians can help prevent falls and 
fractures among older adults. Specifically, we found that THZs and BBs are associated with an elevated 
rate of fractures in the first few weeks after initiation compared to the other classes of antihypertensives. 
These specific medications may be associated with an increased risk of adverse medication events, such 
as orthostatic hypotension or urinary incontinence, causing an increase in falls and subsequent fractures 
after initiation. Older adults initiating with these medications should be made aware of this potential risk 
which may not only help prevent fractures, but also increase overall medication adherence.  We found the 
newer classes of antihypertensive medications, ACEs and ARBs, are associated with lower fracture rates 
after initiation. Clinicians, caregivers, and older adults need to be aware of the potential interactions 
antihypertensives can have with fractures when initiating therapy. When deciding upon antihypertensive 
therapy, clinicians may want to consider the possibility of different drug side effects when choosing 
between antihypertensive drug classes.  
8.3 Future Research 
This was the first study to use GBTMs to identify antihypertensive adherence trajectories among 
older adults initiating therapy. Our results suggest that GBTMs may be a better alternative than traditional 
measures for capturing medication adherence using claims data. One of the inherent disadvantages of 
standard adherence measures (e.g., PDC and PMC) is that they fall short of separating adherence from 
persistence. Our results highlight that one of the benefits of using GBTMs is that they are able to better 
capture changing patterns of use over time. However, our results were not a true comparative analysis of 
adherence measures. Given the novelty of the method, we were interested in examining if the results of 
previous studies would hold true for antihypertensive users in an older adult population.  More research is 
needed using external indicators, such as mortality or cardiovascular events, to validate the benefit of 
using GBTMs over traditional adherence measures. Additionally, future research studies could use 
 76 
GBTMs to identify whether external factors, such as physician visits or adverse medication-related 
events, are influencing fluctuations in medication behavior for intervention purposes.  
 We also found that certain patient characteristics are predictive of being non-adherent. Non-
White race was one of the strongest predictors of being non-adherent. This finding is clinically relevant 
given that hypertension is more prevalent among African Americans older adults.2  However, we were 
unable to conduct separate analysis stratified by race given the small proportion of non-White older adults 
included in our study. More research is needed featuring large non-White populations to identify the 
causes of non-adherence among various race/ethnicity sub-populations.   
 Our results from aim 2 suggest that certain classes of antihypertensive medication may be 
associated with fewer rates of fractures and falls after initiation. However, our study did have some 
limitations. First, our cohort consisted primarily of White older adults. More research is needed using 
different ethnic/racial sub-populations to see if the same findings hold true among these sub-populations. 
Second, we were unable to control for known risk factors of falls and fractures such as: alcohol use, 
baseline BMD, and physical activity. Future research studies combining both clinical and survey data are 
needed to better control for these risk factors. Third, more research is needed to identify the time it takes 
for antihypertensives to have possible BMD effects. Our results suggest that the use of THZs may offer 
protective BMD benefits, but we were unable to clinically measure BMD effects using claims data. More 
research studies are needed featuring clinical BMD measurements to confirm our results. Additionally, 
future research studies with longer follow-up periods are needed to see if the same results hold true over 
longer periods of use.  
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APPENDIX  
 
Figure 8: Guidelines for hypertension management among older adults (JNC8)
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Table 17: Summary of previous research examining the association of antihypertensives and fractures or falls 
Authors Exposure Outcome Covariates 
Study 
Design Population/Data Results 
Ruths et 
al., 2015 67 
THZ, loop 
diuretics, 
CCBs, ACEs, 
ARBs, BBs, 
combination 
drugs 
Incident Hip 
Fractures 
(identified by 
surgical 
records) 
Year of birth, and 
sex 
Cohort 
Norwegian Prescription 
Database, Norwegian 
Hip Fracture Registry, 
and the Central 
Population Registry.  
Study cohort was all 
people aged 60 or older 
living in Norway on 
Jan. 1, 2005.  
Loop diuretics associated with 
an elevated risk of fractures 
within the 14 days of use.  
Most antihypertensives were 
associated with a decreased 
risk of fracture. Lowest risk 
was for ARB/thiazide 
combination users. Association 
varied with age.  
Choi et al., 
2015 61 
ARBs, ACRs, 
ABs*, BBs, 
CCBs, 
diuretics 
Any fracture 
occurring 6 
months after 
the index date 
Age, gender, 
diabetes, 
osteoporosis, 
osteoporosis 
medication, 
osteoporosis 
diseases, Charlson 
index 
New 
User 
Cohort 
Health Insurance 
Review and 
Assessment service of 
South Korea which 
includes patients aged 
50 or older with an 
antihypertensive  
prescription and  
hypertension diagnosis  
ABs were associated with 
increased fracture rates. 
Results differed by gender. 
Females: ARBs associated 
with lowest fracture rate. 
Males: BBs were associated 
with the lowest fracture rate.   
Zia et al., 
2015 30 
Self-reported 
use of ACEs, 
ARBs, BBs, 
CCBs, THZ 
diuretics, 
alpha-
blockers, 
vasodilators 
(included 
combination 
therapy) 
Self-reported 
falls and 
orthostatic 
hypotension 
diagnosed at 
fall clinics 
Age, self-reported 
number of 
comorbidities  
Case-
Control 
Study 
Older adults (65+) who 
went to the emergency 
department or clinic 
due to a fall and who 
enrolled in the 
Malaysian Falls 
Assessment and 
Intervention Trial. 
Cases were older adults 
with two or more falls 
or one injury-fall in the 
last year. Controls were 
sampled from 
population surrounding 
the clinics.  
Alpha blockers and ARBs 
associated with recurrent or 
injury-falls in univariate 
analysis, but not significant 
after adjustment for age and 
comorbidity. Older adults with 
orthostatic hypotension had 
higher odds of taking THZs 
after adjustment for age and 
comorbidity.  OH was not 
associated with recurrent or 
injury-falls.  
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Marcum, et 
al., 2015 62 
BBs, alpha 
blockers, 
potassium-
sparing 
diuretics, loop 
diuretics, THZ 
diuretics, 
CCBs, ACEs, 
ARBs (self-
reported) 
Number of 
self-reported 
falls in the year 
following med 
assessment. 
Primary 
outcome was 
recurrent falls 
(2 or more) 
Demographics, 
health 
behavior/status, and 
access to care 
factors 
Cohort 
Community-dwelling 
older adults (70-79) 
who at baseline 
reported no difficulty 
walking ¼ mile and 
climbing 10 steps who 
were enrolled in the 
Health, Aging, and 
Body Composition  
study 
After adjustment for 
confounders, older adults with 
a history of having a loop 
diuretic filled had higher odds 
of having two or more falls. 
Non-significant, 13% 
increased risk of recurrent falls 
with any antihypertensive use. 
No association according to 
dose and duration of use.  
Lipsitz, et 
al., 2015 64 
Alpha 
blockers, 
ACEs, ARBS, 
BBs, diuretics, 
and CCBs. 
(assessed at 
baseline at 
interviews). 
Dose was 
classified as : 
high, 
low/standard, 
and none 
Self-reported 
recurrent falls. 
Classified by 
location and 
injury. Primary 
outcome was 
more than 1 
fall.  
Baseline blood 
pressure, # of 
comorbidities, 
education, race, 
body mass index, 
psychotropic 
medication use, time 
spent in outdoor 
activities 
Cohort 
598 hypertensive older 
adults (70-97) enrolled 
in the MOBILIZE 
Boston Study 
Fallers were more likely to be 
white, higher educated, higher 
# of comorbidities, prior falls, 
lower cognition, and more 
depressed. During the one year 
follow-up, no class of 
antihypertensive was 
associated with increased risk 
of falls. CCBs were associated 
with a reduced fall risk and 
ACEs were associated with a 
reduced risk of injury falls 
Fraser et 
al., 2014 65 Any 
anticholinergi
c medication 
use (included 
loop diuretic- 
Furosemide) 
Falls and non-
traumatic 
fractures 
Gender, previous 
fracture, diabetes, 
age, femoral neck T-
score, COPD, 
osteoarthritis, 
Parkinson's Disease, 
multiple sclerosis, 
bisphosphonate use 
Cohort 
Adults 50 years of age 
or older enrolled in the 
Canadian Multicentre 
Osteoporosis Study 
(CaMos). 
After adjustment for 
covariates, there was no 
association between ACH use 
and falls or fractures.  
Tinetti et 
al., 2014 114 
ACEs, ARBs, 
BBs, CCBs, 
centrally 
acting 
antiadrenergic 
Serious fall 
injuries 
resulting in 
fracture, brain 
injury, or 
Demographics, 
education, perceived 
health, smoker, 
BMI, insurance, 
blood pressure, 
Cohort  
Community dwelling 
Medicare beneficiaries, 
70+ YOA enrolled 
from 2004-2007 in the 
Medicare Current 
Any antihypertensive use was 
associated with an increased 
risk of having a serious fall 
injury. When stratified by 
class, no class was associated 
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agents, and 
other 
(peripheral 
acting 
antiadrenergic 
agents and 
vasodilators) 
dislocations. 
Did not require 
a fall e-code. 
BADLs, IADLs, 
mobility, social 
activity, urinary 
incontinence, 
cognitive 
incontinence, 
depression, prior fall 
injury, use assistive 
device, osteoporosis, 
prior MI, heart 
failure, diabetes, 
prior stroke, cardiac 
arrhythmia, valvular 
disease, a.fib, 
ESRD, blood loss 
anemia, weight loss, 
PVD, psychosis, 
elixhauser 
comorbidity score, 
statin use, 
medications  history 
Beneficiary Survey 
who had a claim-based 
diagnosis for 
hypertension 
with an increased risk of 
injury. A past fall injury 
greatly increased the risk of a 
fall. Age and gender did not 
impact the association. 
Berry et al., 
2013 109 
New use of 
loop or 
thiazide 
diuretic (new 
used defined 
using 180 day 
washout) 
Hip Fracture 
identified with 
diagnostic and 
procedural 
codes 
Demographics, 
BMI, smoking 
status, fracture 
history, use of 
osteoporosis 
medications 
Case-
crossov
er 
THIN primary care 
database in the UK. 
28,703 persons with hip 
fractures between 
1987-2010.  
Odds of hip fracture were 
increased in the 7 days 
following loop diuretic 
initiation compared to times of 
no use. THZs were associated 
with an increased odds of 
fractures in the 8-14 days 
following use.   
Butt et al., 
2013 63 ACEs, ARBs, 
CCBs, BBs, 
thiazide 
diuretics 
Hip fracture None 
Self-
controll
ed case 
series 
 
Ontario Drug Benefit 
Program hypertensive 
new users of 
antihypertensives 
(mean age:81) 
Antihypertensive initiation 
associated with a 43% 
increased risk of hip fracture in 
45 days after initiation. ACE 
and BB significantly increased 
risk of hip fracture.  
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Berry et al., 
2012 121 
New or 
changing dose 
of diuretics 
(manly loop) 
Incident Fall 
Reported on 
Nursing 
Reports 
None 
Case-
crossov
er 
1,785 long-term care 
nursing home residents 
with a fall history 
(mean age: 86) 
New prescriptions or dose 
increases in loop diuretics were 
associated with increased risk 
of falls. 
Gribbin et 
al., 2011 122 
THZs, BBs, 
ACEs, ARBs, 
CCBs 
Fall None 
Self-
controll
ed case 
series 
 
The Health 
Improvement Network 
(THIN). Patients who 
had a fall and had 
antihypertensives filled 
during the follow-up 
period.  
THZs increase the rate of falls 
in the first 3 weeks following a 
prescription.  BBs associated 
with a slightly elevated risk 
during the first 3 weeks. CCBs 
associated with a decreased 
risk of falls in first 3 weeks 
following use 
Solomon et 
al., 2011 96 
ACEs, CCBs, 
Loop 
diuretics, 
THZs 
Fracture: hip, 
distal forearm, 
humerus, and 
pelvis 
Demographics 
Charlson, hospital 
utilization, med 
history, osteoporosis 
diagnosis or meds, 
prior fractures, 
BMD testing, use of 
meds associated 
with fractures, prior 
fall, Parkinson 
disease and 
Alzheimer disease. 
New 
User 
Cohort 
Medicare beneficiaries 
enrolled in state-run 
drug benefit for low-
income older adults 
with hypertension, no 
prior antihypertensive 
fill in the last 30 days, 
and had health care use 
during the study period.  
No age or gender effects. 
THZs and ARBs associated 
with reduced risk compared to 
CCBs. Examined dose and 
duration effects. Similar to 
main effects. 
Gribbin et 
al., 2010 123 
ACEs, ARBs, 
BBs, CCBs, 
THZs (ever, 
current, 
recent, and 
never 
prescribed) 
 
Falls 
Coronary heart 
disease, heart 
failure, Afib, 
diabetes, Charlson 
index, or prescribing 
of other 
antihypertensives or 
antipsychotics 
Case 
control 
The Health 
Improvement Network 
(THIN). Cases had a 
fall and controls had no 
prior falls. Matched on 
age, sex, and primary 
care practice.  
When comparing never 
prescribed patients to currently 
patients, THZs, BBs, and 
ACEs were associated with 
falls. Association was strongest 
for THZs- risk decreased with 
time. No age effect 
Rejnmark 
et al., 2006 
124 
BBs, ACEs 
and ARBs, 
CCBs 
prescribed 
Any fracture, 
hip fracture, 
spine fracture, 
Charlson index, 
hospital utilization, 
fracture history, 
other meds use: 
Case 
control 
National Hospital 
Danish Register. Cases: 
all subjects who had a 
fracture in 2000. 
BBs: decreased the risk of 
fractures. Dose effect present. 
CCBs: decreased risk of 
fracture. Dose effect was 
  
8
2
 
within 5 years 
of the fracture 
and forearm 
fracture 
diuretics, 
antiresorptive drugs, 
antiepileptic drugs, 
anxiolytics, 
sedatives, 
neuroleptics, 
antidepressants, 
systemic and topical 
corticosteroids, 
thyroid hormones, 
and antithyroid 
drugs. Income, 
social status, 
employment, 
demographics 
Controls:: Civil 
registration system 
mated on gender and 
year of birth.  
found. ACEs were associated 
with a decreased risk of 
fracture. No effect caused by 
age or gender. 
*ABs= adrenergic blockers 
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Table 18: List of antihypertensive drugs included in study according to antihypertensive class 
 Class Generic Drug Names 
ARBs 
 
Azilsartan, Candesartan, Eprosartan, Fimasartan, Irbesartan, Losartan, Olmesartan, 
Tasosartan, Telmisartan, Valsartan 
ACEs 
 
Benazepril, Captopril, Cilazapril, Delapril, Enalapril, Fosinopril, Imidapril, Lisinopril, 
Moexipril, Perindopril, Quinapril, Ramipril, Spirapril, Temocapril, Trandolapril, 
Zofenopril 
CCBs 
 
Amlodipine, Barnidipine, Benidipine, Bepridil, Clinidipine, Clevidipine, Diltiazem, 
Felodipine, Fendiline, Gallopamil, Isradipine, Lacidipine, Lercanidipine, Lidoflazine, 
Manidipine, Nicardipine, Nifedipine, Nilvadipine, Nimodipine, Nisoldipine, Nitrendipine, 
Perhexiline, Verapamil 
BBs 
 
Acebutolol, Alprenolol, Atenolol, Betaxolol, Bevantolol, Bisoprolol, Bopindolol, 
Bupranolol, Carteolol, Carvedilol, Celiprolol, Cloranolol, Epanolol, Esmolol, Labetalol, 
Mepindolol, Metipranolol, Metoprolol, Nadolol, Nebivolol, Netoprolol, Oxprenolol, 
Penbutolol, Pindolol, Practolol, Propranolol, Sotalol, Talinolol, Tertatolol, Timolol 
 
 
THZs 
 
Bendroflumethiazide, Chlorothiazide, Cyclopenthiazide, Cyclothiazide, 
Hydrochlorothiazide, Hydroflumethiazide, Mebutizide, Methyclothiazide, Polythiazide, 
Thiazide, Trichlormethiazide 
 Drugs were identified by generic drug name and National Drug Codes (NDC) in Medicare Part D data.   
Angiotensin converting enzyme inhibitors (ACE), angiotensin receptor blockers (ARB), beta blockers 
(BB), calcium channel blockers (CCB), or thiazide diuretics (THZ) 
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Table 19: List of covariate definitions identified using ICD-9 or CPT Codes 
Covariate Code (includes ICD-9 and CPT Codes) 
Alzheimer’s Disease 3310 
Arrhythmia 4270, 4271, 4272, 42731, 42732, 42741, 42742, 4275, 42760, 42761, 42769, 
42781, 42789, 4279 
Cancer Screen V760, V761, V7610, V7611, V7612, V7619, V762, V763, V7641, V7642. 
V7644, V7645, V7646, V7647, V7649, V7650, V7651, V7652, V768, V7681, 
V7689, V769 
Congestive Heart 
Failure 
428, 4280, 4281, 4282, 42820, 42821, 42822, 42823, 4283, 42830, 42831, 
42832, 42833, 4284, 42840, 42841, 42842, 42843, 4289, 40201, 40211, 
40291, 40401, 40403, 40411, 40413, 40491 
Chronic Kidney 
Disease 
2504, 25040, 25041, 25042, 25043, 27410, 403, 4039, 40390, 404, 4040, 
40400, 40401, 40402, 40403, 4041, 40410, 40411, 40412, 40413, 4049, 
40490, 40491, 40492, 40493, 4401, 4421, 5724, 580, 5800, 5804, 5808, 
58081, 58089, 5809, 581, 5810, 5811, 5812, 5813, 5818, 58181, 58189, 5819, 
582, 5820, 5821, 5822, 5824, 5828, 58281, 58289, 5829, 583, 5830, 5831, 
5832, 5834, 5836, 5837, 5838, 58381, 58389, 5839, 584, 5845, 5846, 5847, 
5848, 5849, 585, 5851, 5852, 5853, 5854, 5855, 5856, 586, 587, 5930 ,5931, 
5932, 5933, 5934, 5935, 5936, 5937, 59370, 59371, 59372, 59373, 5938, 
59381, 59382, 59389, 5939, 753, 7530 ,7533, 7912, 7913, 86600, 86601, 
8661, 86610, 86611, 86612, 86613 
COPD 491, 4912, 49120, 49121 ,49122, 492, 4928, 4932, 4940, 4941, 496,  
Difficulty Walking 7197, 71970, 71975, 71976, 71977, 71978, 71979, 7812, 7813 
Diabetes 2500, 25000, 25002, 25010 ,25012, 2502, 25020, 25022, 2503, 25030, 25032, 
2504, 25040, 25042, 2505, 25050, 25052, 2506, 25060, 25062, 2507, 25070, 
25072, 2508, 25080, 2509, 25090, 25092 
Fracture 820xx,  813xx, 812xx, 8070, 8071, 8072, 8073, 8074, 8056, 8057, 8066, 
8067, 808xx, 824xx,  821xx, 814xx, 815xx, 816xx, 817xx, 823xx, 800xx, 
801xx, 802xx, 803xx, 804xx, 825xx, 826xx, 810xx, 811xx, 822xx 
Hypertension 4010, 4011, 4019 
Myocardial Infarction 410, 4100 ,41001, 4101, 41011, 4102, 41021, 4103, 41031, 4104, 41041, 
4105, 41051, 4106, 41061, 4107, 41071, 4108, 41081, 4109, 41091 
Obesity 27800, 27801, 27803 
Osteoarthritis 71500, 71504, 71409, 71510, 71511, 71512, 71513, 71514, 71515, 71516, 
71517, 71518, 71520, 71521, 71522, 71523, 71524, 71525, 71526, 71527, 
71528, 71530 71531, 71532, 71533, 71534, 71535, 71536, 71537, 71538, 
71580, 71589 
Osteoporosis 73300, 73301, 73302, 73303, 73309 
Parkinson’s Disease 332, 3320 ,3321 
Rheumatoid Arthritis 7140, 7142, 71430, 71431, 71432 
Stroke 430, 431, 432, 4320, 4321, 4329, 4330, 43300, 43301, 4331, 43310, 43311, 
4332, 43320, 43321, 4333, 43330, 43331, 4338, 43380, 43381, 4339, 43390, 
43391, 4340, 43400, 43401, 4341, 43410, 43411, 4349, 43490, 43491, 435, 
4350, 4351, 4352, 4353, 4358, 4359, 436, 4370, 4371, 4372, 4373, 4374, 
4375, 4376, 4377, 4378, 4379, 438, 4380, 43810, 43811, 43812, 43813, 
43814, 43819, 43820, 43821, 43822, 43830, 43831, 43832, 43840, 43841, 
43842, 43850, 43851, 43852, 43853, 4386, 4387, 43881, 43882, 43883, 
43884, 43885, 43889, 4389 
Ambulance Transfer A0426, A0427, A0428, A0429, A0999 
 85 
 
  
Hospital Bed Use E0250, E0251, E0255, E0256, E0260, E0261, E0265, E0266, E0270, E0290, 
E0291, E0292, E0293, E0294, E0295, E0296, E0297, E0301, E0302, E0303, 
E0304, E0316 
Home Oxygen Use E0431, E0433, E0434, E0435, E0439, E0441, E0442, E0443, E1390, E1391, 
E1392 
Walker or Wheelchair 
Use E0130, E0135, E0140, E0141, E0143, E0144, E0147, E0148. E0149, E0154, 
E0155, E0156, E0157, E0158, E1050, E1060, E1070, E1083, E1084, E1085, 
E1086, E1087, E1088, E1089, E1090, E1091, E1092, E1093, E1100, E1140, 
E1150, E1160, E1161, E1170, K0001, K0002,  K0003,  K0004, K0005, 
K0006, K0007, K0008, K0009 
 
  
Vertigo 3860, 38600, 38601, 38602, 38603, 38604, 3861, 38610, 38611, 38612, 
38619, 3862, 3863, 38630, 38631, 38632, 38633, 38634, 38635, 3864, 38640, 
38641, 38642, 38643, 38648, 3865, 38650, 38651,  38652, 38653, 38654, 
38655, 38656, 38658, 3868, 3869, 43885, 7804 
Covariates were identified using Medicare Parts A and B data using International Classification of 
Diseases, Ninth Revision (ICD-9) and Current Procedural Terminology Codes (CPT). 
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Table 20: Trajectory model building results for Medicare beneficiaries initiating antihypertensives 
therapy between 2008-2011 
# Groups  
% Population in Each Group 
BIC Group1 Group2 Group3 Group4 Group5 Group6 Group 7 
2 43.2 56.8 --- --- --- --- --- -1459845 
3 28.5 28.1 43.4 --- --- --- --- -1367868 
4 13.2 28.9 14.2 43.7 --- --- --- -1330199 
5 13.6 15.2 17.2 11.1 42.9 --- --- -1311312 
6 10.4 10.0 18.0 7.9 14.1 39.5 --- -1300277 
7 10.1 5.6 17.4 8.3 7.7 12.1 38.8 -1293649 
BIC= Bayesian information criterion. Lower values signify better model fit.  
Logistic regression models were used to identify trajectory groups. The dependent variables were 
the monthly binary indicators of antihypertensive use and months since start of antihypertensive 
therapy were the independent variables. Time was modeled using cubic terms. 
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Table 21: Comparison of adherence measures ability to distinguish between 
adherent months according to antihypertensive trajectory group 
Trajectory Groups 
Adherence Measure (AUC) 
PDC PMC Traj Model 
Immediate Drop-off 0.609 0.633 0.960 
Rapid Drop-off 0.563 0.581 0.969 
Gradual Drop-off 0.646 0.665 0.789 
Partial Drop-off 0.613 0.646 0.750 
Early Drop-off then Rebound 0.615 0.636 0.797 
Adherent 0.869 0.885 0.660 
Area under the curve (AUC) statistics are used to quantify the ability of the 
measures to discriminate between adherent and non-adherent months. 
Values of 1 symbolize perfect discrimination.   
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Figure 9: Six-group trajectory model excluding those Medicare beneficiaries that were in the insurance 
gap period during follow-up (n=238,925) 
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Table 22: Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for predictors of antihypertensive 
trajectories 
Covariates 
Immediate 
Dropoff Rapid Dropoff Gradual Dropoff Partial Dropoff 
Early Dropoff 
then Rebound 
Male Gender 1.08 (1.06, 1.11) 1.12 (1.08, 1.15) 1.08 (1.06, 1.11) 1.07 (1.04, 1.10) 1.02 (0.99, 1.05) 
Age      
66-74 ref ref ref ref ref 
75-84 1.08 (1.05, 1.11) 1.09 (1.05, 1.12) 1.04 (1.01, 1.06) 1.07 (1.04, 1.11) 1.07 (1.04, 1.10) 
85+ 1.09 (1.04, 1.13) 1.13 (1.07, 1.20) 1.04 (1.00, 1.09) 1.12 (1.06, 1.17) 1.16 (1.11, 1.22) 
Non-White Race 2.05 (1.99, 2.12) 1.85 (1.78, 1.93) 1.59 (1.54, 1.64) 2.26 (2.19, 2.34) 1.58 (1.52, 1.64) 
Combination 
Therapy 0.48 (0.47, 0.50) 0.67 (0.64, 0.70) 0.75 (0.73, 0.78) 0.66 (0.63, 0.69) 0.76 (0.74, 0.80) 
Days supply on 
Index Date 0.98 (0.98, 0.98) 1.02 (1.02, 1.02) 1.01 (1.01, 1.01) 0.99 (0.99, 0.99) 0.99 (0.99, 0.99) 
Medication Use 
14 Days Prior            
1-2 meds ref ref ref ref ref 
3-4 meds 0.96 (0.94, 0.99) 0.97 (0.93, 1.00) 0.94 (0.92, 0.97) 0.93 (0.90, 0.95) 0.94 (0.91, 0.97) 
≥ 5 meds 0.81 (0.78, 0.84) 0.87 (0.83, 0.91) 0.86 (0.83, 0.90) 0.77 (0.74, 0.81) 0.84 (0.80, 0.88) 
Insurance Gap 
During Baseline 0.80 (0.77, 0.82) 0.88 (0.84, 0.92) 0.92 (0.89, 0.96) 0.79 (0.76, 0.82) 0.89 (0.86, 0.93) 
Eligible for Low-
Income Subsidy  0.95 (0.91, 1.00) 0.96 (0.90, 1.02) 0.98 (0.94, 1.04) 1.00 (0.95, 1.06) 0.98 (0.93, 1.04) 
Loop Diuretic  0.86 (0.83, 0.89) 0.93 (0.88, 0.98) 0.98 (0.94, 1.03) 0.91 (0.87, 0.96) 0.98 (0.93, 1.03) 
Antiarrhythmic 1.12 (1.07, 1.18) 1.05 (0.98, 1.13) 1.03 (0.97, 1.09) 1.12 (1.05, 1.20) 1.07 (1.01, 1.14) 
Antidepressanta 1.01 (0.98, 1.04) 1.08 (1.04, 1.13) 1.10 (1.07, 1.14) 1.05 (1.02, 1.10) 1.07 (1.03, 1.11) 
Antiepileptic 1.07 (1.03, 1.11) 1.12 (1.07, 1.18) 1.03 (0.99, 1.08) 0.99 (0.95, 1.04) 1.07 (1.03, 1.12) 
Anxiolytic 1.21 (1.14, 1.29) 1.22 (1.12, 1.33) 1.12 (1.04, 1.20) 1.21 (1.12, 1.30) 1.07 (0.99, 1.16) 
Benzodiazepine 1.01 (0.91, 1.13) 0.88 (0.75, 1.03) 0.94 (0.83, 1.07) 0.88 (0.76, 1.01) 0.95 (0.83, 1.10) 
Opioid 1.33 (1.30, 1.36) 1.18 (1.14, 1.22) 1.16 (1.13, 1.19) 1.26 (1.22, 1.29) 1.19 (1.15, 1.22) 
Hypnotic 1.22 (1.17, 1.27) 1.21 (1.14, 1.28) 1.09 (1.04, 1.14) 1.15 (1.09, 1.21) 1.13 (1.07, 1.19) 
Diabetes 1.01 (0.98, 1.03) 1.13 (1.09, 1.17) 1.09 (1.06, 1.12) 1.16 (1.13, 1.20) 1.16 (1.13, 1.20) 
Chronic Kidney 
Disease 1.03 (0.99, 1.06) 1.05 (1.00, 1.10) 1.06 (1.02, 1.10) 1.08 (1.03, 1.13) 1.09 (1.04, 1.14) 
Parkinson's 
Disease 1.40 (1.29, 1.53) 1.31 (1.16, 1.48) 1.20 (1.09, 1.32) 1.19 (1.07, 1.34) 1.21 (1.08, 1.35) 
Alzheimer’s 0.87 (0.82, 0.93) 0.92 (0.84, 1.01) 0.99 (0.93, 1.07) 0.83 (0.77, 0.91) 0.94 (0.87, 1.02) 
COPD 1.24 (1.20, 1.28) 1.15 (1.10, 1.20) 1.15 (1.11, 1.19) 1.17 (1.13, 1.22) 1.14 (1.10, 1.18) 
Congestive Heart 
Failure 0.90 (0.87, 0.94) 0.93 (0.88, 0.98) 0.99 (0.95, 1.03) 0.98 (0.93, 1.03) 0.95 (0.91, 1.00) 
Arrhythmia 0.77 (0.75, 0.80) 0.87 (0.84, 0.91) 0.88 (0.86, 0.91) 0.76 (0.74, 0.79) 0.85 (0.82, 0.88) 
Osteoarthritis 1.13 (1.09, 1.16) 1.12 (1.08, 1.17) 1.07 (1.04, 1.11) 1.15 (1.11, 1.19) 1.10 (1.06, 1.14) 
Rheumatoid 
Arthritis 1.13 (1.06, 1.20) 1.09 (1.01, 1.18) 1.08 (1.02, 1.16) 1.15 (1.07, 1.24) 1.08 (1.00, 1.16) 
Stroke 0.94 (0.91, 0.97) 1.00 (0.96, 1.04) 0.99 (0.95, 1.02) 0.97 (0.93, 1.01) 1.03 (0.99, 1.07) 
Myocardial 
Infraction 0.50 (0.46, 0.54) 0.66 (0.60, 0.74) 0.78 (0.72, 0.84) 0.52 (0.47, 0.58) 0.67 (0.61, 0.74) 
Hypertension 0.49 (0.48, 0.50) 0.67 (0.64, 0.69) 0.87 (0.84, 0.89) 0.71 (0.69, 0.73) 0.93 (0.90, 0.96) 
Obesity 0.98 (0.93, 1.03) 0.98 (0.92, 1.05) 1.00 (0.95, 1.06) 1.01 (0.95, 1.07) 1.05 (0.99, 1.11) 
Fracture 1.16 (1.12, 1.21) 1.07 (1.01, 1.13) 1.08 (1.04, 1.13) 1.15 (1.10, 1.21) 1.07 (1.02, 1.13) 
Frailty Predictor 
Indexb 0.68 (0.61, 0.76) 0.73 (0.62, 0.85) 0.85 (0.75, 0.96) 0.58 (0.50, 0.67) 0.73 (0.64, 0.84) 
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Home Oxygen 
Use 1.16 (1.09, 1.22) 1.13 (1.04, 1.22) 1.00 (0.94, 1.07) 1.10 (1.03, 1.18) 1.05 (0.98, 1.13) 
Walker or 
wheelchair use 1.01 (0.95, 1.07) 1.05 (0.97, 1.14) 1.00 (0.94, 1.07) 1.12 (1.04, 1.20) 1.05 (0.98, 1.13) 
Hospital Bed 1.21 (1.08, 1.34) 0.91 (0.77, 1.07) 1.06 (0.94, 1.20) 1.12 (0.98, 1.28) 0.97 (0.85, 1.12) 
Difficulty 
Walking 0.99 (0.95, 1.03) 1.03 (0.98, 1.09) 1.00 (0.96, 1.04) 1.00 (0.95, 1.05) 1.00 (0.95, 1.05) 
Vertigo 1.25 (1.21, 1.29) 1.20 (1.15. 1.26) 1.10 (1.06, 1.14) 1.17 (1.12, 1.21) 1.08 (1.04, 1.12) 
Ambulance 
Transport 1.06 (1.02, 1.10) 0.97 (0.92, 1.02) 1.00 (0.96, 1.04) 0.98 (0.93, 1.02) 0.98 (0.94, 1.03) 
Cancer 
Screenings 0.84 (0.82, 0.86) 0.81 (0.79, 0.84) 0.90 (0.88, 0.92) 0.83 (0.80, 0.85) 0.93 (0.91, 0.96) 
Hospital 
Admissions 0.81 (0.69, 0.95) 0.69 (0.54, 0.88) 0.82 (0.68, 0.98) 0.84 (0.68, 1.04) 0.83 (0.68, 1.02) 
Long Stay 
Admissions 1.23 (1.11, 1.37) 1.12 (0.96, 1.32) 1.04 (0.92, 1.18) 1.00 (0.86, 1.17) 1.16 (1.01, 1.33) 
Short Term 
Hospital Stays 1.47 (1.26, 1.72) 1.48 (1.16, 1.88) 1.16 (0.97, 1.39) 1.06 (0.86, 1.31) 1.11 (0.91, 1.35) 
a Antidepressants include selective serotonin reuptake inhibitors, tricyclics, monoamine oxidase inhibitors, serotonin 
and norepinephrine reuptake inhibitors 
b Higher scores denote a higher probability of being frail.  
Odds Ratios (ORs) and 95% CI (confidence intervals) are adjusted for all covariates in table. We presented the 
inverse of the ORs < 1 in the manuscript for consistency relating to non-adherence.  
AUC-statistic for fully adjusted model: 0.525 
Reference group is the adherent trajectory group. 330 observations were removed from the analysis due to missing 
race.  
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Table 23: Definitions of fractures identified in Medicare Claims 
Fracture 
Type 
ICD-9 
Diagnosis 
Codes 
ICD-9 
Procedure 
Codes 
Current Procedure Terminology (CPT)  Codes 
Hip 820.x, 7855, 7905, 
7915, 7925, 
7935, 7965, 
8161, 8162 
27125-27127, 27230, 27232, 27234-27236, 27238, 
27240, 27242, 27244, 27246, 27248, 27130-27131, 
29010, 29015, 29020, 29025, 29035, 29040, 29044, 
29046, 29035, 29325, 29345, 29355, 29358, 29365, 
29505, 29520, 29799, 73500, 73510, 73520, 73530, 
73550 
Radius 813.x, 7853, 7902, 
7912, 7922, 
7932, 7962 
24620, 24625, 24635, 24650, 24655, 24660, 24665-
24666, 24670, 24675, 24680, 24685, 25500, 25505, 
25510, 25515, 25530, 25535, 25540, 25545, 25560, 
25565, 25570, 25575, 25600, 25605, 25610. 25611, 
25615, 25620, 25650, 24580-24581, 24583, 24585-
24588, 29065, 29075, 29085, 29105, 29125-29126, 
29799, 73070, 73080, 73080, 73090, 73100, 73110 
Humerus 812.x, 7852, 7901, 
7911, 7921, 
7931, 7961 
23600, 23605, 23610, 23615, 23620, 23625, 23630, 
23665, 23670, 23675, 23680, 24500, 24505-24506, 
24510, 24515, 24530-24531, 24535-24536, 24538, 
24540, 24542, 24545, 24560, 24565, 24570, 24575-
24581, 24583, 24585-24588, 29035, 29040, 29044, 
29046, 29065, 29105, 29799, 73020, 73030, 73050, 
73060, 73070, 73080 
Rib 8070, 8071, 
8072, 8073, 
8074 
 21800, 21805, 21810, 21820, 21825, 29010, 29015, 
29020, 29025, 29035, 29040, 29044, 29046, 29200, 
71100, 71101, 71110, 71111, 71120, 71130 
Pelvis 8056, 8057, 
8066, 8067, 
808.x 
 27190-27192, 27200, 27202, 27210-27212, 27214, 
27220, 27222, 27224, 27225, 27120, 27122, 27130, 
27131-27132, 72010, 72020, 72100, 72110, 72114, 
72120, 72170, 72170, 72190, 72200, 72202, 72220, 
73500, 73510, 73520, 73530 
Ankle 824.x  27760, 27762, 27764, 27766, 27786, 27788, 27790, 
27792, 27808, 27810, 27812, 27814, 27816, 27818, 
27820, 27822, 27823, 29010, 29015, 29020, 29025, 
29345, 29355, 29358, 29365, 29405, 29425, 29505, 
29515, 29540, 29799, 703328, 70330, 73590, 73600, 
73620, 73630 
Femoral 
Shaft 
821.x  27500, 27502, 27504, 27506, 27508, 27510, 27512, 
27514, 29010, 29015, 29020, 29025, 29035, 29040, 
29044, 29046, 29305, 29325, 29345, 29355, 29348, 
29365, 29505, 29520, 29799, 73500, 73510, 73520, 
73530, 73550 
Hand 814.x-817.x, 7854, 7903, 
7904, 7913, 
7914, 7923, 
7924, 7933, 
7934, 7963, 
7964 
25622, 25624, 25626, 25628, 25630, 25635, 25640, 
25645, 25680, 25685, 26600, 26605, 26607, 26610, 
26615, 26645, 26650, 26655, 26660, 26665, 26720, 
26725, 26727, 26730, 26735, 26740, 26742, 26743-
26744, 26746, 26750, 26755-26756, 26760, 26765, 
25600, 25605, 25610, 25611, 25615, 25620, 25650, 
29035, 29075, 29085, 29105, 29125, 29126, 29130, 
29131, 29799, 73100, 73110, 73120, 73130, 73140 
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Tibia 823.x, 7857, 7906, 
7916, 7926, 
7936, 7966 
27530, 27532, 27534, 27536-27538, 27540, 27750, 
27752, 27754, 27756, 27758, 27780, 27781-27782, 
27784, 27800, 27802, 27804, 27806, 29010, 29015, 
29020, 29025, 29345, 29355, 29358, 29365, 29405, 
29425, 29505, 29515, 29799, 73560, 73562, 73564, 
73590, 73600, 73610 
Skull/Face 800-804.x 767 21300, 21310, 21315, 21320, 21325, 21330, 21335, 
21334-21340, 21345-21347, 21350, 21355, 21360, 
21365, 21380, 21385-21387, 21390, 21395-21400, 
21401, 21406-21407, 21420-21422, 21431, 21432-
21433, 21435, 21440, 21445, 21450, 21451-21455, 
21461, 21462, 21465, 24170, 21495, 70230, 70231, 
70250, 70260, 
Foot 825.x-826.x, 7858, 7907, 
7908, 7917, 
7918, 7927, 
7928, 7938, 
7967, 7968 
28400, 28405-28406, 28410, 28415, 28420, 28430, 
28415, 28450, 28430, 28435-28436, 28440, 28445, 
28450, 28470, 28475-28476, 28480, 28485, 28 490, 
28495-28496, 28500, 28505, 28510, 28515, 28520, 
28525, 29405, 29425, 29505, 29515, 29550, 29580, 
73600, 73620, 73630, 73650, 73660 
Clavicle 810.x-811.x  23500, 23505, 23510, 23515, 23570, 23575, 23585, 
29010, 29015, 29020, 29025, 29035, 29040, 29044, 
29046, 29049, 29055, 29058, 29065, 29105, 29240, 
7300, 73010, 73020, 73030, 73050, 73060 
Patella 822.x 7856 27520, 27522, 27534, 29010, 29015, 29020, 29025, 
29035, 29040, 29044, 29046, 29345, 29355, 29358, 
29365, 29355, 29358, 29365, 29435, 29505, 29530, 
73550, 73560, 73562, 73564, 73590 
Fractures were identified using validated diagnosis codes and procedure codes found in Medicare Parts 
A and B 99. Fractures included in the study had an incident diagnosis code with a corresponding 
procedure code within 7 days of the diagnosis.  
 
 
 
 
  
 93 
Table 24: List of covariate definitions identified using ICD-9 or CPT Codes 
Covariate Code (includes ICD-9 and CPT Codes) 
Ambulance Transfer A0426, A0427, A0428, A0429, A0999 
Alzheimer’s 
Disease 3310 
Arrhythmia 4270, 4271, 4272, 42731, 42732, 42741, 42742, 4275, 42760, 42761, 42769, 42781, 
42789, 4279 
Cancer Screen V760, V761, V7610, V7611, V7612, V7619, V762, V763, V7641, V7642. V7644, 
V7645, V7646, V7647, V7649, V7650, V7651, V7652, V768, V7681, V7689, V769 
Chronic Kidney 
Disease 
2504, 25040, 25041, 25042, 25043, 27410, 403, 4039, 40390, 404, 4040, 40400, 40401, 
40402, 40403, 4041, 40410-40413, 4049, 40490, 40491, 40492, 40493, 4401, 4421, 5724, 
580, 5800, 5804, 5808, 58081, 58089, 5809, 581, 5810-5813, 5818, 58181, 58189, 5819, 
582, 5820, 5821, 5822, 5824, 5828, 58281, 58289, 5829, 583, 5830, 5831, 5832, 5834, 
5836, 5837, 5838, 58381, 58389, 5839, 584, 5845-5849, 585, 5851-5856, 586, 587, 5930- 
5937, 59370-59373, 5938, 59381, 59382, 59389, 5939, 753, 7530 ,7533, 7912, 7913, 
86600, 86601, 8661, 86610-86613 
Dementia 290, 294 
Difficulty Walking 7197, 71970, 71975, 71976, 71977, 71978, 71979, 7812, 7813 
Diabetes 2500, 25000, 25002, 25010 ,25012, 2502, 25020, 25022, 2503, 25030, 25032, 2504, 
25040, 25042, 2505, 25050, 25052, 2506, 25060, 25062, 2507, 25070, 25072, 2508, 
25080, 2509, 25090, 25092 
Dyslipidemia 272-272.5 
Hospital Bed Use E0250, E0251, E0255, E0256, E0260, E0261, E0265, E0266, E0270, E0290, E0291, 
E0292, E0293, E0294, E0295, E0296, E0297, E0301, E0302, E0303, E0304, E0316 
Home Oxygen Use 
E0431, E0433, E0434, E0435, E0439, E0441, E0442, E0443, E1390, E1391, E1392 
Hypertension 4010, 4011, 4019 
Myocardial 
Infarction 
410, 4100 ,41001, 4101, 41011, 4102, 41021, 4103, 41031, 4104, 41041, 4105, 41051, 
4106, 41061, 4107, 41071, 4108, 41081, 4109, 41091 
Obesity 27800, 27801, 27803 
Orthostatic 
Hypotension 4580 
Osteoarthritis 
71500, 71504, 71409, 71510-71518, 71520-71528, 71530-71538, 71580, 71589 
Osteoporosis 73300, 73301, 73302, 73303, 73309 
Parkinson’s Disease 332, 3320 ,3321 
Rheumatoid 
Arthritis 7140, 7142, 71430, 71431, 71432 
Stroke 430, 431, 432, 4320, 4321, 4329, 4330, 43300, 43301, 4331, 43310, 43311, 4332, 43320, 
43321, 4333, 43330, 43331, 4338, 43380, 43381, 4339, 43390, 43391, 4340, 43400, 
43401, 4341, 43410, 43411, 4349, 43490, 43491, 435, 4350, 4351, 4352, 4353, 4358, 
4359, 436, 4370-4379, 438, 4380, 43810, 43811-43814, 43819, 43820, 43821, 43822, 
43830, 43831, 43832, 43840, 43841, 43842, 43850, 43851, 43852, 43853, 4386, 4387, 
43881-43885, 43889, 4389 
Syncope 
7802 
Urinary 
Incontinence 7883 
Walker or 
Wheelchair Use E0130, E0135, E0140, E0141, E0143, E0144, E0147, E0148. E0149, E0154, E0155, 
E0156, E0157, E0158, E1050, E1060, E1070, E1083, E1084, E1085, E1086, E1087, 
E1088, E1089, E1090, E1091, E1092, E1093, E1100, E1140, E1150, E1160, E1161, 
E1170, K0001, K0002,  K0003,  K0004, K0005, K0006, K0007, K0008, K0009 
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Vertigo 3860, 38600, 38601, 38602, 38603, 38604, 3861, 38610, 38611, 38612, 38619, 3862, 
3863, 38630, 38631, 38632, 38633, 38634, 38635, 3864, 38640, 38641, 38642, 38643, 
38648, 3865, 38650, 38651,  38652, 38653, 38654, 38655, 38656, 38658, 3868, 3869, 
43885, 7804 
Covariates were identified using Medicare Parts A and B data using International Classification of Diseases, 
Ninth Revision (ICD-9) and Current Procedural Terminology Codes (CPT). 
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Table 25: Sensitivity analysis results examining the rates of incident non-vertebral fractures in the first year after initiation  
among Medicare beneficiaries initiating antihypertensive monotherapy from 2008-2011 according to duration of use 
  0-14 days after initiation 15-365 days after initiation 
Drug 
Class 
# 
Fractures P-Yrs 
Rate Per 10,000  
p-yrs  (95% CI) 
 SMRW HR 
(95% CI) 
# 
Fractures P-Yrs 
Rate per 10,000 
 p-yrs  (95% CI) 
 SMRW HR 
(95% CI) 
Results when using an ‘As-Treated’ study design (n=122,629) 
ACE 52 1,502 346 (261-451) ref 735 21,726 338 (315-363) ref 
ARB 14 410 342 (194-559) 0.96 (0.50, 1.82) 177 5,973 299 (255-343) 0.90 (0.76, 1.07) 
BB 55 1,373 401 (302-521) 1.04 (0.67, 1.60) 842 19,802 425 (397-455) 1.18 (1.05, 1.33) 
CCB 24 679 354 (232-518) 0.76 (0.45, 1.28) 432 9,534 453 (412-497) 1.14 (1.00, 1.31) 
THZ 27 595 454 (305-651) 1.48 (0.82, 2.67) 277 7,932 349 (310-392) 0.99 (0.84, 1.18) 
Results when excluding beneficiaries with chronic kidney disease or diabetes (n=86,420) 
ACE 32 979 327 (227-456) ref 781 23,373 334 (211-358) ref 
ARB <11 NR 300 (139-569)  0.94 (0.40, 2.22) 199 6,398 211 (270-357) 0.95 (0.81, 1.12) 
BB 45 1,045 431 (318-571) 1.35 (0.81, 2.26) 1000 24,799 403 (330-488) 1.07 (0.96, 1.19) 
CCB 19 513 370 (230-568) 0.97 (0.53, 1.81) 522 12,116 431 (395-469) 1.13 (1.00, 1.27) 
THZ 22 505 436 (280-649) 1.30 (0.74, 2.30) 459 12,031 382 (348-418) 1.04 (0.92, 1.18) 
Results when excluding beneficiaries that initiated with brand antihypertensive medications on the index date (n=108,491) 
ACE 54 1,529 353 (268-457) ref 1,277 37,716 339 (320-358) ref 
ARB <11 NR 370 (94-1,008) 0.80 (0.24, 2.63) 67 1,997 336 (262-423) 0.99 (0.76, 1.30) 
BB 51 1,294 394 (297-514) 0.90 (0.58, 1.42) 1,267 31,800 398 (377-421) 1.08 (0.99, 1.19) 
CCB 25 637 393 (260-571) 0.82 (0.49, 1.37) 659 15,648 421 (390-454) 1.11 (1.00, 1.24) 
THZ 27 614 441 (296-632) 1.40 (0.78, 2.51) 563 15,105 373 (343-405) 1.02 (0.90, 1.15) 
P-Yrs= person-years of follow (calculated by dividing the total number of follow-up days by 365.25) 
SMRW= Standardized mortality ratio weight 
Hazard ratios are adjusted for SMRWs that were calculated using all the baseline covariates. 
NR= non-reportable 
CI=confidence interval 
Angiotensin converting enzyme inhibitors (ACE), angiotensin receptor blockers (ARB), beta blockers (BB), calcium channel 
blockers (CCB), or thiazide diuretics (THZ) 
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Figure 10: Eligibility flow chart of Medicare beneficiaries starting antihypertensive monotherapy between 
2008-2011 
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Figure 11: Adjusted SMR Kaplan-Meier curves for incident fractures according duration of use (1-14 
days after initiation and 15-365 days after initiation) according to antihypertensive drug class among 
Medicare beneficiaries starting antihypertensive monotherapy. Top figure=1-14 days after initiation. 
Bottom figure=15-365 days after initiation.  
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Table 26: Antihypertensive adherence trajectory model building results (Chapter 6) 
# Groups  
% Population in Each Group 
BIC Group1 Group2 Group3 Group4 Group5 Group6 Group 7 
2 42.89 57.11 --- --- --- --- --- -1078223 
3 28.08 28.14 43.78 --- --- --- --- -1010901 
4 13.46 28.61 13.83 44.10 --- --- --- -983827 
5 13.97 15.06 17.33 10.77 42.86 --- --- -970453 
6 15.67 20.26 5.36 6.49 9.04 43.19 --- -963983 
BIC= Bayesian information criterion. Lower values signify better model fit.  
Logistic regression models were used to identify trajectory groups. The dependent variables were 
the monthly binary indicators of antihypertensive use and months since start of antihypertensive 
therapy were the independent variables. Time was modeled using cubic terms. 
6 group failed to converge and had small group sizes 
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Table 27: Rates of death and disenrollment from Medicare according to one year antihypertensive adherence trajectories following initiation 
of therapy 
182 Day Period  365 Day Period  
Drug Class 
# Deaths 
/Disenroll 
Person-
Years 
(p-yrs) 
Rate Per 10,000 
p-yrs (95% CI) 
  Adjusted HR 
 (95% CI) 
# Deaths 
/Disenroll 
Person-
Years 
(p-yrs) 
Rate per 10,000 
p-yrs  (95% CI) 
  Adjusted HR  
(95% CI) 
Immediate Drop-off 1,418 46,351 306 (290, 322) 1.30 (1.22, 1.39) 2,778 61,066 455 (438, 472) 1.25 (1.20, 1.31) 
Gradual Drop-off 1,561 53,364 293 (278, 307) 1.27 (1.19, 1.35) 3,060 70,356 435 (420, 451) 1.22 (1.67, 1.27) 
Partial Drop-off 954 33,157 288 (270, 306) 1.28 (1.19, 1.37) 1,859 43,735 425 (406, 445) 1.22 (1.53, 1.28) 
Early Drop-off then Rebound 1,170 43,026 272 (257, 288) 1.19 (1.11, 1.28) 2,444 56,749 431 (414, 448) 1.22 (1.16, 1.28) 
Adherent  2,952 132,187 223 (215, 232) ref 6,069 174,808 347 (339, 356) ref 
Hazard Ratios (HRs) are adjusted for all baseline covariates. CI= Confidence Interval 
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